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The Road goes ever on and on 
Down from the door where it began 
Now far ahead the Road has gone, 
And I must follow, if I can, 
Pursuing it with eager feet, 
Until it joins some larger way 
Where many paths and errand meet. 
And whither then? I cannot say. 
 The Old Walking Song 
 
All that is gold does not glitter, 
Not all those who wander are lost; 
The old that is strong does not wither, 
Deep roots are not reached by the frost. 
 The Riddle of Strider 
 
 
 
The Lord of the Rings 
By J.R.R. Tolkien
 
 
 
 
 
 
 
 
To my dear wife, Rongrong, 
 
To my parents, Margareta and Alexander,  
 
To my siblings, Anna and Alex 
 
      
 
 
 
 
 
 
 
Your vision will become clear only when you look into your heart. Who looks outside, dreams.  
Who looks inside, awakens.      
               – Carl Gustav Jung
 
  
ABSTRACT 
Rheumatoid arthritis (RA), the most common inflammatory arthritis, is a chronic, potentially 
debilitating autoimmune disease that can lead to functional disability, bone erosion, and 
chronic pain. The modern era of treatment has led to major advancements in treating this 
condition, especially if patients are treated early within a ‘window of opportunity’ with potent 
disease-modifying antirheumatic drugs (DMARDs) and a ‘treat-to-target’ approach aiming 
towards low disease activity or remission. Personalized integrative medicine may lead to 
further advancements in the care of individuals suffering from autoimmune conditions such 
as RA through the application of imaging, biomarker and risk factor identification, and 
integrative manual therapy. 
After simulating a true radiographic progression control group in several randomized clinical 
trials, early application of intensive or biological DMARDs was demonstrated to be superior 
to conventional monotherapy in early RA, and that rheumatoid factor-positive patients on an 
intensive strategy may benefit more with a half-year induction of anti-tumor necrosis factor 
(TNF) therapy (Papers I-II).  
For the first time, it was revealed that the proto-oncogene survivin, expressed in one third of 
patients with early RA, prevents a sustained clinical response to gold-standard methotrexate. 
Additionally, further allocation to combination DMARDs may be favorable to the allocation 
of anti-TNF therapy among survivin-positive patients (Paper III).  
Lifestyle risk factors were shown to play an important role in early RA disease outcome, and 
obesity in particular was found to be a strong independent predictor of long-term non-
remission, in addition to smoking. Obesity was associated with worse clinical outcomes over 
time, measured by disease activity, pain, and functional disability (Paper IV).  
A novel approach was explored with integrative manual mobilization therapy and its potential 
to further enhance patient care in RA. This was demonstrated through systemic subjective 
and objective hand improvements – including pain, synovial fluid, and joint space (Paper V).  
Together with the goal of aiming for early, tight RA disease control, when utilizing imaging 
tools; identifying biomarkers and lifestyle risk factors; and applying integrative medicine, 
allopathic practice can move towards even better proactive patient care in RA. Altogether, 
these findings support the value of incorporating personalized integrative medicine into 
clinical practice for patients with RA.  
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1 INTRODUCTION 
1.1 PRELUDE 
With the impact of innovations through western allopathic medicine, public health, and 
industrialization to abrogate infectious diseases and significantly prolong life, modern 
humanity has been able to convert itself in a stepwise fashion from a state of – paraphrasing 
the words of Professor Hans Rosling – ‘dying in ecological balance’ to that of ‘living in 
ecological balance.’ 
Now in the modern era with advanced nations taking small steps towards science fiction 
becoming the reality, our globe – in addition to the cumbersome weight of political, ethical, 
and environmental concerns – is faced with new challenges: the ever-advancing, looming 
shadow and inescapable burden of chronic illnesses. To tackle these challenges, the novel 
scientific minds of our age are advocating personalized medicine, where – through 
knowledge and identification of biomarkers and genetic expression – the design and 
allocation of therapies can be targeted to individuals instead of populations.  
Through the studies included in this thesis book that centralize around rheumatoid arthritis, 
the intention was to investigate the advances of allopathic medicine upon tackling challenges 
with personalized care: through proper identification and treatment of individuals by imaging 
techniques, biomarkers, and environmental & lifestyle risk factors; yet, to also potentially 
help fill a void in the care paradigm. Perhaps by taking a more inclusive medical approach, 
chronic illnesses and the surging problem of disarray, stress, and psychosocial issues could be 
further eased through a combined approach; namely, personalized integrative medicine.  
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1.2 RHEUMATOID ARTHRITIS 
Rheumatoid arthritis (RA) is a chronic autoimmune disease and the most prevalent 
inflammatory arthritis – affecting around 0.5-1% of adults in high-income countries, and is 
two to three times as common among women (1-4). RA has an estimated global prevalence 
of 0.24% due to regional fluctuations: being highest in Oceania, North America, and Western 
Europe (0.45%); while being lowest in East/Southeast Asia, North Africa, and the Middle 
East (0.16%) (5). About two-thirds of patients with RA have autoantibodies, and the 
condition is characterized by elevated acute-phase reactants, swollen and tender joints due to 
synovial inflammation, functional disability, work productivity losses, bone erosion, and 
chronic pain; and is also associated with an enhanced risk of cardiovascular morbidities (1-
10).  
Disease-modifying anti-rheumatic drugs (DMARDs) in particular, whether synthetic or 
biological – in addition to non-steroidal anti-inflammatory drugs (NSAIDs) – are utilized in 
the management of patients with RA. These treatments are today capable of inducing 
increasingly-achievable states of remission (11), however, it has been identified that even 
some of these patients, despite clinical response, lose health-related functional capability over 
time (12). Efforts have been made by the European League Against Rheumatism (EULAR) 
and the American College of Rheumatology (ACR) – the two largest international research 
organizations within rheumatology – in creating the 2010 classification criteria for RA, which 
may help patients to get treated in time by a ‘window of opportunity’ with early, aggressive 
therapy (13, 14). This stratagem has been shown to be more efficacious than standard of care 
in the clinical setting (15, 16).  
There exist, however, several avenues which have not been carefully addressed prior to the 
work demonstrated in this thesis. Namely, exactly how early, intensive therapy in a large 
randomized trial in early RA might benefit patients by radiographic imaging in relation to 
true control projections through linear modelling; the clinical value of predictive biomarkers 
and risk factors in early RA; and the potential importance of monitoring patients with early- 
to established RA through integrative medicine with manual mobilization therapy. 
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1.3 OUTLINE 
In this thesis, the following background topics will be covered: 
 A background of RA, including its preclinical stage and pathogenesis, diagnosis, as 
well as allopathic treatment strategies.  
 Imaging tools utilized in RA, including conventional radiographic analysis, 
musculoskeletal ultrasound, and a brief mentioning of novel imaging instruments. 
 Predictive and associative biomarkers, including how they may play a role in RA, as 
well as how they may potentially predict disease course.  
 Lifestyle and environmental risk factors as potentially influential determinants of 
pathogenesis and predictors of disease activity in RA.  
 Integrative medicine, where complementary treatment modalities are included 
together with allopathic medicine. Here, a description of various integrative 
modalities will be laid out, in addition to a summary of the literature pertaining to 
integrative medicine tested in autoimmune rheumatic conditions thus far. 
 
The thesis then includes the original research addressed through Papers I-V, including:  
 An overarching aim and study-specific aims for each paper. 
 Materials and methods for each paper. 
 Study-specific results, points for discussion, and conclusions.  
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2 BACKGROUND 
2.1 RHEUMATOID ARTHRITIS IN DEPTH 
2.1.1 Pathogenesis and promulgation 
There is increasing evidence that the body reveals important pathogenic signs prior to disease 
onset in autoimmune conditions such as RA (17-25). Monitoring these markers, and thereafter 
responding with therapy, may provide a ‘window of opportunity’ for action in early RA – within 
three months to maximum two years after symptom onset (26, 27) – to prevent outcomes which 
could later become potentially irreversible.  
Autoreactive B cells that differentiate into plasma cells (PCs) are capable of producing anti-
citrullinated protein antibodies (ACPA) and rheumatoid factor (RF), which have been found to 
be present in individuals who would later develop RA several years afterward (21-23). Although 
RF is traditionally associated with RA, it does not specifically identify RA as it is present in 
several inflammatory conditions, and appears to be involved in T cell-related immunity to 
immunoglobulin G (IgG) immune complexes (28-30). ACPA, on the other hand, is more RA-
specific as these antibodies occur in <2% of healthy individuals and are only marginally present 
in other inflammatory conditions (28). ACPA specificities in RA include citrullinated epitopes 
as antigens on vimentin, fibrinogen, α-enolase, histones, type II collagen, and tenascin C (28, 31-
36). Somatic hyper-mutation and affinity maturation in the follicles/germinal centers of lymph 
nodes allows for highly specialized B cells and their antibody progeny to effectively respond to 
antigens. However, this specialization may decrease affinity and thus increase autoreactivity – 
creating antibodies like ACPA or RF. This, together with genetic and environmental risk factors, 
may lead to the initiation and prolongation of inflammation/bone erosion in RA (2, 28, 37, 38).   
RA may be initiated and prolonged through the formation of several potential stakeholders. The 
most widely-accepted, evidence-based environmental trigger is smoking (39-45) – especially 
upon combination with the HLA-DRB1 shared epitope (SE) and PTPN22; as these genes are 
especially susceptible RA risk candidates of protein citrullination caused by smoking and 
triggering the immune system by ACPA as a result (28, 32, 37-39, 46). Alternative triggers 
include exposure to silica (47, 48), textile dust (49), and possibly some microorganisms (50-52). 
The cascade then begins with (citrullinated) antigen presentation and co-stimulation, where 
dendritic cells (DCs) and autoreactive B cells activate the effector functions of T cells at 
mucosal sites: the lungs, gums, or gut (28, 38); leading to pro-inflammatory cytokines such as 
 6 
tumor necrosis factor (TNF), interleukin (IL)-6, interferon-γ, and lymphotoxin-α (37); as well as 
ACPA/RF autoantibodies and the resulting formation of immune complexes. Finally, ectopic 
lymphoid structures are present in ~40% of patients with RA and can form in the sublining of 
the synovial tissue surrounding the joints (53), as well as extra-articular sites such as the lungs 
and bone marrow (54, 55). They are induced by cytokines such as lymphotoxin-α1-β2, 
chemokines such as B lymphocyte chemoattractant CXCL13, and vascular adhesion molecules 
such as VCAM1; and display functional germinal center features with autoreactive B cells, T 
cells, follicular dendritic cells (FDCs), and PCs that are capable of releasing localized cytokines, 
chemokines, and autoantibodies (37, 53, 56-58). These elements, in their own way, shape, or 
form, play an individualized role in the creation and sustainability of adaptive autoimmunity in 
RA (Figure 1). 
Once the pathogenesis and promulgation of RA has been set in motion, synovial cells and the 
joint microenvironment are activated and infiltrated by peripheral immune cells – the result 
being synovitis or inflammation of the synovium and the formation of the pannus, which 
degrades cartilage and erodes bone (2, 59). RA, however, can manifest through several different 
pathways; subdivided for example into at least three possible microstructural synovial 
phenotypes: lymphoid: follicular synovitis with B- and T cells that form ectopic lymphoid 
structures: myeloid: diffuse infiltration pattern of monocytes and macrophages (Mɸ); and 
fibroid: minimal synovitis with limited to no immune cell infiltration (53, 60-64). An example of 
a metacarpophalangeal joint of the hand affected by RA synovitis is shown in Figure 2A-B. 
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Figure 1. Pathogenesis and promulgation of autoimmunity in rheumatoid arthritis 
In the pre-arthritis phase of rheumatoid arthritis (RA), environmental exposures in the form of 
pollutants (smoking) or microorganisms (bacteria), mucosal surfaces are triggered and post-
translational modification can ensue with citrullination of vimentin, fibrinogen, α-enolase, 
histones, type II collagen, and tenascin C. Risk genes associated with anti-citrullinated protein 
antibodies (ACPA), such as HLA-DRB1 shared epitope (SE) and PTPN22, can trigger pollutant-
based exposures – set forth first through antigen presentation by professional antigen-presenting 
cells (dendritic cells (DC) and B cells) and co-stimulation of T cells in lymph nodes. T helper 2 
(Th2) cells are then able to activate the differentiation of autoreactive B cells to produce 
autoantibodies such as ACPA or rheumatoid factor (RF) which can gather as immune 
complexes. Ectopic lymphoid structure neogenesis through resulting cytokines, chemokines, and 
immune cell infiltration can also be triggered and form in the sublining of synovial tissue – with 
follicular dendritic cells (FDC) and B cells in the core of its apparent germinal center, 
surrounded by T cells and later by autoantibody-secreting plasma cells (PCs). Autoimmunity in 
RA is then promulgated from proinflammatory cytokines such as tumor necrosis factor (TNF) 
and interleukin 6 (IL-6) (1, 2, 28, 37, 38, 53).  
T/BCR, T/B cell receptor; MHC II, multihistocompatability complex class II; CD, cluster of 
differentiation. 
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Figure 2B. Synovitis caused by rheumatoid arthritis in the metacarpophalangeal joint 
An example of a metacarpophalangeal hand joint affected by rheumatoid arthritis (RA). The 
unaffected portion on the lower end of the joint (bottom of Figure 2A) shows normal synovial 
tissue and healthy bone and cartilage. The affected portion on the top of the joint (zoomed in 
here in 2B) highlights ectopic lymphoid structures of B- and T cells, follicular dendritic cells 
(FDC), antigen-presenting cells such as macrophages (Mɸ), fibroblast-like synoviocytes (FLS), 
and plasma cells (PCs): an environment of autoimmune inflammation trapped in a chronic loop. 
PC-secreted autoantibodies such as anti-citrullinated protein antibodies (ACPA) and rheumatoid 
factor (RF) contribute to joint inflammation by targeting antigens (ACPAs target citrullinated 
antigens (CA) such as vimentin and fibrinogen) and form immune complexes (IC) which can 
engage Mɸ to secrete pro-inflammatory cytokines classic to RA: tumor necrosis factor (TNF) 
and interleukin 6 (IL-6). Upon activation by the auto-antigenic milieu, FLS, like Mɸ, secrete  
IL-6 and matrix metalloproteinases (MMPs), leading to biomechanical dysfunction. FLS 
inflammatory activation leads to a rapid increase in synovial cell number (synovial hyperplasia), 
and they also introduce chemokine CXCL8, which, together with ACPA binding, induce 
osteoclasts (OCs) to proliferate and erode bone and cartilage, releasing additional CXCL8. In 
addition to triggering pain through nociceptive nerves, CXCL8 can also draw in neutrophils to 
eventually release neutrophil extracellular traps (NETs), with citrullinated histones captured by 
ACPA to promote further NETosis and resulting inflammation. At the vanguard of the invasive 
synovial hyperplasia is the pannus, eating away at cartilage and bone (1, 2, 28, 53, 59).  
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2.1.2 Classification criteria 
2.1.2.1 Older rheumatoid arthritis classification criteria 
 
Prior to the joint venture of ACR and EULAR to develop the new RA classification criteria at 
the turn of the current decade in 2010 (13, 14), the older 1987 revised RA criteria (Table 1) by 
the ACR (formerly known as the American Rheumatism Association, ARA) had been utilized 
for over 20 years in diagnosing and classifying RA – with a sensitivity from 91-94% to a 
specificity of 89% for correct classification in comparison to controls with other rheumatic 
diseases (65). Prior to this, the 1958 revised criteria of the ARA were the most widely used for a 
long period of time – but were eventually challenged and changed to the 1987 criteria due to the 
risk of inaccuracy, extensive criterion, and unnecessary invasive procedures (65, 66).  
Despite having good classification accuracy for established RA, the 1987 ACR criteria were 
challenged by their inaccuracy in identifying individuals with RA at an early stage (67). This is 
due to the fact that these criteria were formed to discriminate patients with established RA from 
those with other rheumatic diagnoses; thus, they weren’t designed to identify patients who could 
benefit from early intervention – which became one of the most important modern paradigms: 
treating patients within the aforementioned ‘window of opportunity’ could prevent the chronic, 
erosive disease state highlighted by the 1987 criteria (13, 14, 26, 27). 
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Table 1 – Summary of the 1987 ACR classification criteria for RA by traditional format 
1987 American College of Rheumatology (ACR) criteria for rheumatoid arthritis (RA), adapted 
from ref (65).  
In order for a patient to be classified with RA, four out of the seven above criterion must be met. 
Criteria 1-4 must be present ≥6 weeks. Patients with two clinical diagnoses are not excluded, 
and designation by classic, definite, or probable RA as in the 1958 revised criterion is not to be 
made. 
*14 possible joint areas (right/left): PIP, proximal interphalangeal joints; MCP, 
metacarpophalangeal joints, wrists, elbows, knees, ankles, and MTP, metatarsophalangeal joints. 
Bilateral involvement without absolute symmetry is acceptable for PIP/MCP/MTP.  
  
Criterion Description  
1. Morning stiffness 
2. Arthritis of ≥3 joint areas* 
3. Arthritis of hand joints* 
4. Symmetric arthritis* 
5. Rheumatoid nodules 
6. Serum rheumatoid factor 
7. Radiographic changes 
Morning stiffness in/around joints ≥1 hour before maximal improvement 
Simultaneous soft tissue swelling/fluid: PIP/MCP/wrist/elbow/knee/ankle/MTP 
≥1 swollen area (as defined above) in a wrist/MCP/PIP joint 
Simultaneous bilateral joint involvement of the same joint areas 
Subcutaneous nodules over bony prominences/extensor/juxtaarticular regions 
Abnormal serum rheumatoid factor: <5% of normal control subjects 
Posteroanterior hand/wrist radiographic changes typical of RA, which must 
include erosions/unequivocal bony decalcification  localized in or adjacent to 
involved joints (osteoarthritis changes alone do not qualify) 
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2.1.2.2 New rheumatoid arthritis classification criteria 
 
The new 2010 classification criteria (Table 2) were prepared by a joint ACR/EULAR working 
group with three phases of development, the first two being: 1) identifying variables to predict 
the decision to give methotrexate (MTX) in an early undifferentiated arthritis population (68), 
and 2) using real-life patient cases to address rheumatologist-based decisions on the contribution 
of each variable in influencing the probability of developing RA (69). The resulting four criteria 
formed the basis of the final criteria set (phase three), which were published both in the EULAR 
(13) and ACR (14) flagship journals. Here, definite RA according to these new criteria (score 
≥6) had proportions of 97%, 91%, and 87% in three different cohorts of patients treated with 
MTX within a year from onset of symptoms. 
Studies have since confirmed that the new 2010 ACR/EULAR criteria have acceptable 
discriminative ability in classifying more patients with early RA, who may have otherwise been 
classified as having undifferentiated disease (70-74), although there are also limitations as the 
new criteria may identify less autoantibody positive patients and more with monarthritis (71), 
and they could possibly overdiagnose very early RA (75). Nonetheless, it does appear that the 
new 2010 criteria are superior in discriminative capacity when compared to the older 1987 
criteria (76). They have a good overall sensitivity performance (0.82), although the overall lower 
specificity (0.61) needs to be taken into consideration for potential improvements in the future 
(77). A EULAR task force has thus far added an erosive disease definition for use in the 2010 
ACR/EULAR criteria for patients who had radiographic erosions in at least three separate joints 
but did not otherwise meet the 2010 criteria (score of <6 points) (78). 
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Table 2 – Summary of the 2010 ACR/EULAR classification criteria for RA 
2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) 
criteria for rheumatoid arthritis (RA), adapted from ref. (13, 14).  
* Aimed at classifying newly-onset patients. Patients with RA-typical erosive disease, or long-standing 
disease with a history compatible with prior 2010 criteria fulfillment should be classified with RA. Other 
diseases: expert rheumatologist should be consulted if unclear. ** Status reassessment possible over time 
if not fulfilling 6/10 criteria. *** Any swollen/tender joint which may be confirmed by synovitis imaging 
evidence (distal interphalangeal (DIP), first carpometacarpal-, and first metatarsophalangeal (MTP) joints 
are excluded). Joint distribution categories classified by location and number of involved joints; highest 
category placement based on joint involvement pattern. Large joints: shoulders/elbows/hips/knees/ankles. 
† Small joints: Metacarpophalangeal-, proximal interphalangeal (PIP), MTP II-V, and thumb 
interphalangeal joints and wrists. †† Any combination of large- and additional small joints.  
‡ Negative: ≤ upper limit of normal (ULN) for lab/assay; low-positive: >ULN but ≤3xULN; high-
positive: >3xULN. If only RF is available, a positive should be scored as low-positive for RF. ‡‡ Patient-
reported symptom duration of signs/symptoms of synovitis.  
Target population, who should be tested? 
1. Patients who have ≥1 joint with definite clinical synovitis (swelling)* 
2. Patients with synovitis not better explained by another disease* 
Classification criteria for RA: a score-based algorithm of the sum of categories A-D,  
where a score ≥6/10 is needed for classification of a patient as having definite RA** 
A. Joint involvement *** Score 
  1 large joint *** 
  2-10 large joints 
  1-3 small joints (with/without involvement of large joints) † 
  4-10 small joints (with/without involvement of large joints) 
  >10 joints (at least one small joint) †† 
0 
1 
2 
3 
5 
B. Serology (≥1 test result needed for classification) ‡  
  Negative rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPA) 
  Low-positive RF or ACPA 
  High-positive RF or ACPA 
0 
2 
3 
C. Acute-phase reactants (≥1 test needed for classification)  
  Normal C-reactive protein (CRP) and erythrocyte sedimation rate (ESR) 
  Abnormal CRP and ESR 
0 
1 
D. Duration of symptoms ‡‡  
  <6 weeks 
  ≥6 weeks 
0 
1 
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2.1.3 Treatment  
2.1.3.1 Synthetic, biological, and novel disease-modifying antirheumatic agents 
Traditionally, the treatment for RA involves the combination of conventional synthetic 
DMARDs – MTX being the gold standard – with glucocorticoids and NSAIDs. In cases of non-
response, more intensive treatment with conventional triple therapy (TT: MTX + sulfasalazine 
(SSZ) + hydroxychloroquine (HCQ)) can be administered. Otherwise, expensive biologics that 
typically come in the form of humanized or chimeric monoclonal antibodies may be necessary. 
Biologics are indicated in particular for patients who do not respond through the conventional 
approach, and they include anti-TNF agents (infliximab, etanercept, certolizumab-pegol, 
golimumab, and adalimumab) and agents with other modes of action (IL-1 receptor antagonist, 
anakinra; T cell costimulation inhibitor, abatacept; anti-CD20 (B cell) agent, rituximab; and IL-6 
receptor inhibitor, tocilizumab) (79-82).  
More recently, the first targeted synthetic DMARD for RA (small-molecule inhibitor) blocking 
the intracellular Janus kinase/signal transducer and activator of transcription (JAK-STAT) 
pathway via JAK1 and 3, tofacitinib, was approved by the United States Food and Drug 
Administration (FDA) for moderate to severe RA as of November, 2012, and has been utilized 
first in the United States, Russia, and Japan (83). Due to the demonstrated efficacy, tofacitinib 
and the newer JAK1-2 inhibitor, baricitinib, are included as possible treatment options in the 
latest EULAR treatment guidelines (84). The European Medicines Agency (EMA) had initially 
rejected tofacitinib’s approval due to safety concerns, but has now in January 2017 forwarded its 
recommendation to the European Commission; two months after recommending baricitinib.  
Additionally, it is now recognized that biosimilars – less expensive, near-identical copies of the 
original biologic product upon patent expiration – are as effective as their originators; and that 
targeting the IL-6 pathway or ligand through novel biologics sarilumab, clazakizumab, 
sirukumab; or granulocyte-monocyte colony stimulating factor receptor α inhibition with 
mavrilimumab, can provide potential benefits in RA (82, 84).   
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2.1.3.2 Rheumatoid arthritis treatment paradigms and recommendations 
It has been demonstrated that, just as by treating within a ‘window of opportunity,’ a more 
effective strategy than routine care is to plan treatment goals with patients by aiming to achieve 
remission or low disease activity – a concept called ‘treating to target’ or ‘treat-to-target’ (T2T) 
(85, 86), which has been gaining ample systematic evidence pointing to its superiority to routine 
care (87). The initial 2010 T2T strategy formed by a panel of rheumatology experts resulted in 
10 recommendations, with the ultimate goal of remission (or low disease activity in patients with 
long-standing disease); to be achieved by following-up with patients with active disease every 
one to three months, and followed by appropriate therapeutic management to reach the ultimate 
goal within three- to a maximum of six months (85). It has since been updated in 2014, with the 
same amount of recommendations but with the order changed in addition to partial adaptations 
as deemed necessary (88).  
The four overarching principles in 2014 T2T for RA (88) are as follows:  
 A. Treatment must be based on shared patient and rheumatologist decision-making. 
 B. The primary goal should be to maximize long-term health-related quality of life 
through symptom control, structural damage prevention, and normalization of function 
and participation in social and work-related activities. 
 C. Abrogation of inflammation is the most important way to achieve these goals. 
 D. T2T by measuring disease activity and adjusting therapy optimizes outcomes. 
For the management of RA, a merged summary of the 2016 EULAR treatment 
recommendations (84) can be found in Figure 3. These were an update of the 2013 
recommendations (81, 83), further informed by the efficacy of older and new biologics, 
including biosimilars; more data on novel synthetic JAK inhibitors (tofacitinib, baricitinib); and 
information on switching, spacing, and dose reduction strategies (82).  
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Treatment should begin as soon as possible, and it should have a T2T initiative. 
Disease activity should be monitored every 1-3 months if possible and therapy should 
be adjusted upon no improvement in 3 months, or if not meeting T2T by 6 months
MTX (or, with contraindications/intolerance: sulfasalazine or leflunomide) 
should be part of the (first) treatment strategy
Short-term glucocorticoids should be considered when 
initiating/changing conventional synthetic DMARDs, in different 
dose regimens and routes of administration, but should be tapered 
as rapidly as deemed clinically feasible
Upon first DMARD failure, change to another conventional DMARD. 
When conventional DMARDs fail (or upon first failure with poor 
prognostic factors), change to a biologic (anti-TNF agent/abatacept/ 
tocilizumab/rituximab) or biosimilar; or alternatively a JAK inhibitor
Biologics or JAK inhibitors should be combined with a conventional 
DMARD. In patients who cannot use conventional DMARDs as 
comedication, IL-6 or JAK inhibitors may have some advantages 
compared with other biologics
In the event that the biologic or JAK inhibitor fails, another biologic or JAK 
inhibitor should be considered. 
If one TNF inhibitor has failed, patients may receive another TNF inhibitor 
or an agent with another mode of action
If a patient remains in persistent remission and has successfully had tapering of 
glucocorticoids, tapering of a biologic can be considered, especially if combined with a 
conventional DMARD; and tapering of conventional DMARDs can be considered with 
sustained long-term remission but should be done with care
Strategize 
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Figure 3. Concise summary of the EULAR 2016 updated recommendations for the 
management of rheumatoid arthritis (RA) with synthetic or biological disease-
modifying antirheumatic agents (DMARDs), adapted from ref. (84) 
T2T, Treat-to-target (aim: low disease activity/remission); MTX, methotrexate; TNF, 
tumor necrosis factor; JAK, Janus kinase; IL-6, interleukin 6. 
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2.2 IMAGING 
As patients who may be in clinical remission by the 28-joint count disease activity score 
(DAS28) (89) are still able to develop health-related functional disability (12), so too can these 
patients also develop bone erosions (termed radiographic progression) according to the Sharp-
van der Heijde (SHS) scoring method, as was shown in the group of patients who responded to 
(and remained on) MTX monotherapy in the randomized care-based Swedish pharmacotherapy 
(SWEFOT) trial (90). This stresses the importance of imaging as a necessary gold standard for 
verifying whether or not a patient is indeed in remission.  
 
2.2.1 Conventional radiography 
X-ray analysis has for a long time served as the conventional method of imaging-based 
diagnosis and prognosis in rheumatology. Although X-rays do not show signs of ongoing 
inflammation and have limitations in detecting early disease, they reveal erosions and joint-
space narrowing; and also correlate with physical function – a highly important indicator of 
long-term outcomes (91-93). The most widely used conventional radiographic scoring method in 
rheumatology is SHS, which has an erosive component where an analyst scores 32 joints in the 
hands and wrists and 12 in the feet; as well as a joint-space narrowing component, which scores 
30 joints in the hands and wrists and 12 in the feet. The total score is the summed score of both 
components, the maximum being 448 (94, 95).  
 
2.2.2 Musculoskeletal ultrasound and other novel instruments 
Although conventional radiography is still recommended over clinical criteria alone as one of 
the imaging modalities to be used when there is an uncertainty of diagnosis, musculoskeletal 
ultrasound and magnetic resonance imaging have instead rather recently been accepted as new 
gold standards of imaging in rheumatology by EULAR – in the sense that they are superior to 
conventional radiography in detecting inflammation and disease progression (96). Ultrasound, 
for example, has been shown to improve diagnostic certainty of an auto-inflammatory condition 
through the testing of a probabilistic Bayesian analysis (97). Finally, even more novel 
instruments such as fluorescence optical imaging – which utilizes an intravenous fluorescent dye 
that emits visible light after excitation by light at short wavelengths – was shown through one of 
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our studies to have good agreement with ultrasound and is capable of detecting clinically non-
apparent synovitis (98). Beyond the scope of this thesis, we are further evaluating this method in 
how it may help with diagnostic certainty through a probabilistic Bayesian analysis. 
 
2.2.3 A novel approach with conventional radiography 
If novel and expensive instruments would not be available, however, there is a method by which 
radiographic progression may be predicted by using conventional radiography and symptom 
duration before diagnosis, whereby the simulation of bone erosion or joint-space narrowing over 
time (as if patients were not on treatment) is created. Although not an exact representation of a 
true control group, as radiographic progression is not entirely linear, the prediction offered by 
this method (Predicted vs. Observed Progression in early RA, POPeRA) has first been shown by 
Wick et al. as being most similar to the outcomes of non-responders to treatment (99). This was 
later demonstrated in Paper I, where the POPeRA method was applied to the randomized 
SWEFOT trial (100). Here, the original SWEFOT findings – that radiographic efficacy of anti-
TNF treatment over TT were significantly apparent after two years (101, 102) – were also tested 
to determine if potential radiographic progression could be prevented more among anti-TNF 
than TT (100). Paper II utilized POPeRA to potentially confirm or add new insights into the 
original findings from the randomized Finnish RA Combination therapy (FIN-RACo) and New 
Finnish RA combination therapy (NEO-RACo) trials (103).  
The first publication that utilized the POPeRA method by Wick et al. compared MTX with SSZ 
and with auranofin, a now out-of-phase DMARD also known as oral gold. Here, after one year, 
patients on either MTX or SSZ had significant reductions from predicted; however, the 
auranofin group had similar progression to predicted – as did another group deemed a control 
due to a lack of response to several medications (99).  
Naturally, patients with RA are to be treated immediately upon diagnosis. Therefore, the 
simulation that POPeRA provides – which is an approximation of how patients would progress 
as if not on treatment – is a vital method for validating the relative radiographic efficacy of 
various DMARDs. 
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2.3 BIOMARKERS 
For those who have RA, despite sharing the same diagnosis, every patient represents a case 
study due to their unique profile of genetic background and environmental exposures. 
Biomarkers are unique indicators (typically proteins) which have associative or predictive roles 
in inflammation, aspects of disease activity, or prognosis. The biomarkers RF and ACPA (e.g. 
against fibrinogen, vimentin, and α-enolase), together with acute-phase reactants C-reactive 
protein (CRP) and/or erythrocyte sedimentation rate (ESR), are the only major associative 
biomarkers to inflammation and disease activity utilized as part of standard clinical practice in 
rheumatology and RA. There exist, however, a multitude of other biomarkers that have entered 
the knowledgebase in the field, such as anti-collagen II, anti-binding Ig protein, anti-
peptidylarginine deiminases, and anti-histones (28, 46).   
Novel, standalone biomarkers such as cellular signaling protein 14-3-3η, or the inhibitor of 
apoptosis, survivin, have been shown to be associated with radiographic progression and worse 
outcome (104-107). As elevated survivin can also signal the onset of RA (108), Paper III was 
conducted to assess the clinical value of elevated survivin levels and how it may potentially 
predict therapy responses in early RA (109).  
An intriguing concept is the combination of several pro-inflammatory markers, acute-phase 
reactants, and matrix metalloproteinases (MMPs) combined together to form a multi-biomarker 
disease activity (MBDA) score, which – with a high score at baseline – has been able to predict 
worse radiographic progression over one year (110, 111); and, when combined with ACPA, can 
predict relapses in over 80% of patients (112). Finally, it is worth mentioning that randomized 
controlled trials in RA often exclude patients with low CRP (≤10 mg/L). Patients with a high 
MBDA score despite low CRP were found to have outcomes comparable to patients with a high 
CRP; thus, recruitment in clinical trials can be substantially enhanced with the inclusion of this 
metric (113).  
Despite a bold undertaking, the results thus far indicate that the investigation of biomarkers may 
point to successful prospects for healthcare, where personalized medicine could one day become 
a reality to achieve.  
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2.4 RISK FACTORS: ENVIRONMENT AND LIFESTYLE 
2.4.1 Known environmental risk factors in rheumatoid arthritis 
As introduced earlier, smoking is a strong trigger for RA onset (39-45), particularly when 
combined with genetic factors (HLA-DRB1-SE, PTPN22) (28, 32, 37-39, 46). Smoking has also 
been shown to be a strong independent predictor of radiographic progression in early RA in the 
SWEFOT trial (114), in addition to being a risk factor for MTX failure (115). Silica (47, 48) and 
textile dust (49) as potentially hazardous occupational exposures for construction- and textile 
workers – and, possibly, invasive microorganisms (50-52) – are additional risk factors according 
to most studies for the development of RA that can trigger autoimmunity at mucosal sites (28, 
38). 
 
2.4.2 Lifestyle risk factors in rheumatoid arthritis 
Poor diet/nutrition such as elevated salt intake (116) may be a potential RA risk factor, 
particularly at a younger age (117, 118). Fortunately, a relatively recent popular field of 
investigation in RA is diet; the consumption of fish-derived omega-3 fatty acids in particular. A 
large meta-analysis in 2014 found a 20-24% reduced risk of RA with one to three servings of 
fish per week when compared to never-consumption, although it wasn’t statistically significant 
(119). Nonetheless, a large prospective cohort study of women the same year found a significant 
35% risk reduction of developing RA if consuming fish >0.21 g/day; and by an even greater 
amount (52% reduced risk) if this amount of consumption was maintained for 10 years (120). 
Omega-3 also has documented modest effects on reducing pain and inflammation in RA (121). 
More recently, it has been shown to be associated with refractory pain suppression (122); and 
high-dose fish oil supplements might even increase remission rates (123). Interestingly, it has 
been recently implicated that omega-3 may be of particular benefit for preventing ACPA-
positive RA and protecting RA-susceptible individuals with the risk gene, HLA-DRB1-SE (124, 
125). 
Poor diet – together with the increased prevalence of sedentary behavior in RA (126) – brings 
forth the question of one of its consequences: an elevated body mass index (BMI). BMI, 
obtained by dividing weight by the squared height, is divided into four categories: obese 
(BMI≥30 kg/m²), overweight (25-29.9), normal (18.5-24.9), and underweight (<18.5), 
respectively. Obesity and overweight have been recognized as an epidemic in modernized and 
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urbanizing countries alike (127), and their link to metabolic syndrome and diabetes are concerns 
in and of themselves. An elevated BMI (overweight, and obesity in particular) has been 
identified in a meta-analysis of eleven studies as a potential risk factors for developing RA 
(128), and the risk may be higher among seropositive smokers (129). A large population-based 
study – corrected for potential confounders including smoking – indicated a reduced risk of 
developing RA among overweight or obese men, but not among women (130). Prior to this, an 
even larger prospective observational cohort of female registered nurses found that being 
overweight or obese contributed to the risk of developing RA, either seropositive or seronegative 
(131).  
An elevated BMI has previously been associated with persistent disease activity/non-remission, 
functional impairment, and pain; as well as a lower odds of a good treatment response in early 
RA (majority on MTX) (132). Similar findings, with obesity in particular, have been observed in 
other observational studies, mostly in established RA (reviewed in: 133, 134). On the other 
hand, an elevated BMI has also been shown to be associated with less radiographic damage 
(133, 135). Paper IV was thus conducted with data from the SWEFOT trial to determine the 
potential clinical and predictive role of BMI (obesity) in the randomized setting of early RA.  
  
  23 
2.5 INTEGRATIVE AND COMPLEMENTARY MEDICINE 
2.5.1 What is it? 
Due to the global popularity of non-allopathic complementary and alternative medicine (CAM) 
and traditional medicine (TM), the National Institutes of Health of the United States were 
pushed to set up a tailored division of research: the National Center for Complementary and 
Integrative Health (NCCIH) (formerly NCCAM), which today funds CAM- or TM-specific 
studies. Despite large investments in North America, Asia, and Australia for CAM or TM 
research – and despite the European Commission taking interest in the matter – the majority of 
European countries (including Sweden) are lagging behind in research of complementary 
medicine primarily due to scarce funding (136). In research, the term CAM is a catchy acronym 
that is still used but could be considered somewhat out of phase in the sense that the ‘alternative’ 
aspect refers to treatments taken instead of conventional allopathic medicine (137), which is 
unusual in the West and would not be recommendable, especially pertaining to autoimmune 
conditions where tight disease control is required. Many modern approaches outside of 
allopathic medicine with a sound scientific basis such as manual therapy – despite having roots 
at least as far back as the established Father of Medicine, Hippocrates (138) – could be regarded 
by some as falling into the ‘complementary’ category, but it is perhaps even less fitting for other 
practices intricately tied to culture that originate thousands of years earlier than allopathic 
medicine. According to the World Health Organization (WHO), TM ranges from ancient 
Chinese or Indian health-related practices such as tai chi, qigong, acupuncture, meditation, or 
yoga; to medication-based approaches such as herbal Ayurveda, Arabic unani, and other 
indigenous medicines (139).  
Complementary medicine according to NCCIH can be divided into ‘natural products’ (vitamins 
and herbal supplements) and ‘mind and body practices’ (manual mobilization or manipulation, 
massage, therapeutic touch, and relaxation therapy; but also includes TM practices such as 
acupuncture and yoga). Importantly, NCCIH stresses the importance of ‘integrative medicine,’ 
which is the practice of merging allopathic with non-allopathic medicine cooperatively (137). In 
a unified approach, WHO has decided upon the acronym, traditional and complementary 
medicine (T&CM), to refer to the very broad spectrum of non-allopathic methods (140). In the 
context of this thesis, it will generally be referred to as integrative and complementary medicine, 
or simply, integrative medicine. 
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2.5.2 Prevalence of integrative and complementary medicine 
Results from a nationally representative survey in the United States performed in 1990 and 1997 
found that there was a substantial increase in the use of at least one integrative and 
complementary medicine within the previous year, from 33.8% to 42.1%; that seeking out a 
complementary practitioner also increased substantially (36.3% to 46.3%); and that, despite the 
increase in complementary medicine use, the low disclosure rate to doctors and large proportion 
of patients paying entirely out of pocket for complementary care remained similar over time 
(39.8% vs. 38.5%; 64.0% vs. 58.3%, respectively) (141). The national survey also revealed that 
expenditures on complementary care alone equated to $30 billion per year – which, at that time, 
even exceeded the country’s out-of-pocket payments for allopathic treatments prescribed by 
primary care physicians (141, 142). The prevalence of complementary medicine use and out-of-
pocket payments has remained stable since (143).  
Results from WHO’s 2002-2005 TM strategy estimate the European national use of integrative 
and T&CM at least once per lifetime as being 75% (France), 70% (Canada), 48% (Australia), 
and 38% (Belgium) (139). China and India have a very prevalent TM integration in health care. 
Chinese TM, unlike in the West, is integrated in hospitals and exclusive TM-based pharmacies 
exist. No less than 40% of all healthcare services delivered in China is through Chinese TM 
alone (139). In India, the use of Indian TM such as Ayurveda or yoga for primary health care 
equated to as much as 70% (139). Largely as a result of the 2002-2005 initiative, the number of 
WHO Member States that have implemented either T&CM policies, or regulated herbal 
medicine, have greatly increased from 25 and 65 in 1999, respectively; to 69 and 119 in 2012, 
respectively (140). Despite the large prevalence of integrative and complementary medicine 
globally and its noticeable popularity, finding funding for well-controlled studies is extremely 
challenging. Cochrane systematic reviews in turn report the difficulties of appropriate 
methodology for its research and find only a tendency towards a possibility of positive effects 
for several non-allopathic medicines, including acupuncture, tai chi, yoga, manual therapy, 
massage, and others (144). 
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2.5.3 Integrative care of autoimmune conditions 
Studies powered and funded adequately that may be able to give us insight on the prevalence of 
the use of integrative and complementary medicine and its effectiveness in autoimmune diseases 
are scarce; and are, at best, only a relatively new phenomenon. Cochrane systematic reviews 
have thus far been able to summarize that, for RA, balneotherapy (spa therapy) does not have 
enough evidence to show effectiveness (145); physical activity and psychosocial interactions 
have a beneficial effect on self-reported fatigue (146); electroacupuncture is capable of reducing 
knee pain but more evidence is warranted due to methodological flaws (147); tai chi has 
significantly beneficial effects on the lower extremities of motion (148); and oils containing 
gamma linolenic acid have moderate evidence of symptom relief, while Tripderygium wilfordii 
Hook F (TwHF) (thunder god vine) – a Chinese TM herbal therapy which has already been 
integrated in Chinese rheumatology practice for decades – provides symptom relief but could 
lead to mild to moderate adverse events if administered orally (149). Well after these systematic 
reviews were conducted, a carefully-constructed randomized controlled trial was published in 
the New England Journal of Medicine and demonstrated that tai chi had major benefits for 
subjects with fibromyalgia (150), a complex pain syndrome that is more prevalent among 
patients with RA and other rheumatic conditions. Additionally, a relatively recent, open-label 
randomized controlled trial demonstrated that TwHF has comparable efficacy to MTX against 
disease activity in active RA, and is also statistically superior to MTX monotherapy when both 
are combined; with a relatively good safety profile (151).  
In Sweden, one study has thus far mapped out the use of integrative and complementary 
medicine among outpatients with inflammatory rheumatic conditions (152). The prevalence was 
65%; and patients who sought out complementary care had more often poorer health, indicative 
of non-response to conventional therapy. Stress has been shown to predict fatigue and pain 
(153); which may influence patients to seek out complementary care for qualitative purposes 
that allopathic medicine alone might otherwise not be able to address.  
The effects of integrative or complementary medicine can also be measured quantitatively. We 
first performed a pilot study involving patients with RA who were non-responders to 
antirheumatic therapy, to determine if a manual therapy treatment method that is normally used 
for pain relief in osteoarthritis (OA) – manual mobilization of the extremities, founded upon 
conventional medical principles of anatomy, physiology, physiotherapy, and manual therapy; 
and developed by the Norwegian physiotherapist Freddy Kaltenborn (154-156) – could also be 
effective in RA. In three treatment sessions within a week, 20 metacarpophalangeal (MCP) hand 
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joints (MCP II-V of one hand) were treated with repeated Kaltenborn within-the-slack Grade I-II 
manual mobilizations – which sufficiently provides movements of traction to counteract 
compressive joint forces but avoids soft tissue stretching (154, 156) – both for safety and 
feasibility, as well as monitoring a potential dose-based response over time. After one week, 
pain and tenderness decreased significantly, and inflammation as assessed via musculoskeletal 
Doppler ultrasound decreased by a mean of 21% from baseline to post-final treatment (157, 
158). These results motivated the creation of a larger randomized crossover pilot study  
(Paper V), which also included a hand OA comparator group and a longer follow-up period, in 
order to investigate the potential effectiveness of integrative medicine in more novel manners, 
not only qualitatively, but quantitatively. 
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3 OVERARCHING AIM 
The overall aim of this thesis was to evaluate personalized integrative medicine, by: 
 Reviewing the state of established knowledge pertaining to RA, including its 
pathogenesis, clinical course, classification, and treatment paradigms.  
 
 Identifying imaging modalities, biomarkers, environmental and lifestyle risk factors, 
and integrative medicine of potential importance for RA. 
 
 Investigating the disease course of RA through predicting – with the simulative 
capacity of POPeRA and radiography (imaging); the theranostic capability of serum 
survivin (biomarkers); and the clinical importance of BMI and lifestyle factors  
(risk factors) in disease outcome – as well as monitoring RA outcome with the 
applied approach of integrating manual therapy with the standard of care (integrative 
medicine). 
  
 28 
3.1 STUDY-SPECIFIC AIMS 
3.1.1 Paper I 
The first paper sought to apply the POPeRA method, previously called ‘Estimated 
prediagnosis radiological progression’ (99), to a large randomized clinical trial in early RA 
(SWEFOT) to verify its original findings – that anti-TNF infliximab therapy was 
radiographically superior to TT over two years (101, 102). The primary outcome of POPeRA, 
however, was to specifically determine if anti-TNF could prevent more potential radiographic 
progression than TT, as the radiographic progression in this case is a simulation of how 
patients with early RA would progress without DMARDs. Thereby, the comparison to actual 
radiographic findings can be done, and % reduction from predicted can be compared across 
treatments.  
 
3.1.2 Paper II 
The second paper sought to apply the POPeRA method and verify or add insight to the 
findings of two large randomized clinical trials in early RA (FIN-RACo and NEO-RACo) by 
determining how various treatments can prevent radiographic progression as the primary 
outcome. FIN-RACo originally found that intensive DMARD combination therapy (TT with 
glucocorticoids) was radiographically superior to monotherapy (primarily SSZ or MTX) over 
two and five years (159, 160), and NEO-RACo originally found that intensive combination 
therapy + six-month induction of anti-TNF infliximab was only superior to intensive 
combination therapy + placebo at two years, but not at five years (161, 162). 
 
3.1.3 Paper III 
The proto-oncogene survivin has previously been shown to be elevated in pre-RA individuals 
(108), and has in RA been associated with erosive disease, RF/ACPA, and smoking (105-
107). Due to the lack of literature on how survivin might affect therapeutic clinical choices, 
the aim of the third paper was to determine the clinically-predictive role of survivin as a 
potential theranostic (selective targeted therapy) biomarker. Primary outcomes included 
assessment of the clinical ‘core set’ (DAS28, HAQ, and the 0-100 mm visual analog scale for 
pain (VAS-pain) and global health (VAS-global)) over 2 years. 
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3.1.4 Paper IV 
Due to the previously observed discordance between worse clinical outcomes, pain, and 
function, but better radiographic outcomes related to elevated BMI (obesity and/or 
overweight), particularly in established RA (132-135, 163, 164), we sought to investigate the 
potentially predictive role of obesity with clinical and radiographic outcomes in the 
randomized SWEFOT trial in the early RA setting (101, 102). Outcomes were the clinical 
‘core set’; EULAR non-remission (DAS≥2.6), EULAR good response, and radiographic 
progression (SHS≥1; SHS≥5) over two years. 
 
3.1.5 Paper V 
Despite major advancements in the care of patients with RA (165), pain remains a persistent 
concern – even when patients respond well to DMARDs (166). Thus, the initiative to find a 
complementary method of care to potentially integrate into the practice of rheumatology has 
been in need. After the promising results of an initial pilot study that achieved successful 
short-term control of pain and even inflammation in RA (157, 158), the aim of the final paper 
was to take a longer-term prospective experimental approach in the care of patients with RA 
in a larger randomized crossover pilot study to assess the clinical feasibility, safety and 
effectiveness of Kaltenborn manual mobilization in RA compared to a clinical comparator 
group with hand OA. The primary outcomes of the study was assessment of the hands with 
VAS-pain, physician’s tender/swollen joint count; as well as quantitative (%) Doppler signal, 
synovial fluid, and MCP joint space by musculoskeletal ultrasound.  
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4 MATERIALS AND METHODS 
4.1 THE SWEDISH PHARMACOTHERAPY TRIAL 
Papers I, III, and IV are based on the patient populations with early RA from the SWEFOT 
trial. SWEFOT was a two-year multicenter open-label randomized clinical trial in early RA 
conducted in Sweden from 2002-2005 and was one of the first to apply the modern T2T 
approach (85, 88) in advance, aiming for low disease activity or remission (101, 102). All 
patients were first allocated to MTX monotherapy for three to four months, and, of the 
remaining 403 patients, 258 did not respond to MTX (DAS28≤3.2) and were randomized 
either to treatment intensification with TT or with add-on of anti-TNF infliximab. The 
primary endpoint was a EULAR good response (present DAS28≤3.2 and a ΔDAS28 
improvement >1.2) at 12 and 24 months of follow-up, where radiographic damage by SHS 
was also assessed (Figure 4). 
 
 
Figure 4. Schematic of the randomized clinical SWEFOT trial 
RA, rheumatoid arthritis; DMARD, disease-modifying antirheumatic drug; DAS28, disease 
activity score; MTX, methotrexate; SSZ, sulfasalazine; HCQ, hydroxychloroquine; anti-TNF, 
anti-tumor necrosis factor; EULAR, European League Against Rheumatism. See ref. (101). 
  
  31 
4.2 THE FIN-RACO AND NEO-RACO TRIALS 
Paper II included patients with early RA from the FIN-RACo (159, 160) and NEO-RACo 
(161, 162) trials, including data from the primary two-year endpoints as well as the more 
recent five-year follow-ups. Like SWEFOT, both FIN-RACo and NEO-RACo were already 
built on a T2T approach and were an inspiration for T2T when it became official as of 2010 
(85).  
FIN-RACo was a two-year multicenter Finnish randomized early RA clinical trial conducted 
from 1993-1995 (159). Of 195 patients, 97 were randomized to intensive combination TT 
(MTX+SSZ+HCQ with glucocorticoids) and 98 to DMARD monotherapy (primarily SSZ or 
MTX, with or without glucocorticoids). A five-year follow-up was also carried out (160), and 
the primary outcomes were preliminary ACR strict remission (167) and radiographic damage 
by the Larsen score (168). NEO-RACo was another two-year multicenter Finnish randomized 
early RA clinical trial, conducted from 2003-2005 (161). Of 99 patients, 50 were randomized 
to receive intensive combination TT with a six-month induction of anti-TNF infliximab, 
versus 49 who were randomized to intensive combination TT with a six-month induction of 
placebo. A five-year follow-up was also carried out (162) and the primary outcomes were the 
same as in FIN-RACo, except that SHS was also available for radiographic damage scoring. 
 
4.3 THE POPERA METHOD IN EARLY RHEUMATOID ARTHRITIS 
The POPeRA method (99) was applied in Papers I-II, where 343 patients from SWEFOT; 
144 from FIN-RACO; and 90 from NEO-RACo had available radiographic scores at all time 
points. The radiographic score upon early RA diagnosis at baseline (SHS for SWEFOT and 
NEO-RACO, and Larsen for FIN-RACo) was first divided by the patient-reported symptom 
duration in months before baseline to obtain an inferred progression rate (IPR) (see below). 
The radiographic score at symptom onset is assumed to be zero (thus the x-intercept). 
Following this calculation, each time point in months was multiplied by the IPR, and then 
added to the baseline radiographic score. Altogether, this formula simulates linear 
progression as if the patient were not treated – thus generating a true control reference value 
that can be compared to observed progression. A detailed figure of the POPeRA technique 
can be found in Paper I (100). To include as many patients as possible into the model (some 
started with a score of zero that was maintained throughout the follow-ups), all radiographic 
scores were imputed with an increase of one unit. 
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Formula for calculating the IPR, required for calculating the predicted progression score: 
  𝐼𝑃𝑅 =
Radiographic score [baseline SHS or Larsen]
Symptom duration [months before baseline]
 
Formula for calculating predicted radiographic progression (PRP) in SWEFOT (Paper I):   
PRP score [12;  24 months]
= IPR x 12 + baseline SHS;  IPR x 24 + baseline SHS   
Formula for calculating PRP in FIN-RACo (Larsen) and NEO-RACo (SHS) (Paper II):   
PRP score [24;  60 months]
= IPR x 24 + baseline score;  IPR x 60 + baseline score   
 
 
4.4 SERUM SAMPLES, ENZYME-LINKED IMMUNOSORBENT ASSAY 
For Paper III, available stored frozen serum samples at -80 °C from baseline – and from 3, 
12, and 24 months – from 302 early RA SWEFOT patients were organized and sent for 
analysis so that a sandwich enzyme-linked immunosorbent assay (ELISA) (DYC647, R&D 
Systems, Minneapolis, MN, USA; detection limit 0.1 ng/mL) (105, 169) could identify 
survivin positivity by a matched-antibody pair (rabbit anti-human survivin), with a threshold 
>0.45 ng/mL indicating positivity – being present in <5% of healthy controls (105, 170). 
 
4.5 BODY MASS INDEX 
For Paper IV, BMI was calculated from available baseline data of height (meters, m) and 
weight (kg) from 260 patients with early RA in the SWEFOT trial. BMI was calculated by 
kg/m2 into its respective scale, and was also converted into BMI categories: obese (≥30 
kg/m²; n=43), overweight (25-29.9; n=74), and normal (18.5-24.9, n=143). One patient was 
underweight (<18.5) and was included under normal due to a BMI close to the normal 
threshold (17.9). 
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4.6 THE INTEGRATIVE KALTENBORN MANUAL MOBILIZATION STUDY 
Paper V is a novel randomized blinded crossover pilot study that integrates established 
manual therapy into conventional rheumatology practice, and was carried out in the 
Rheumatology Clinic of the Karolinska University Hospital in Solna. Here, 12 research 
participants with RA were recruited who were also patients receiving standard of care with 
background medication, including either conventional or biological DMARDs. A clinical 
comparator group was also included, consisting of eight research participants with hand OA, 
which is a more common manual therapy target group. For primary measures, 320 hand 
joints were assessed.  
All participants were recruited from February 2015 to December 2016 through the 
Rheumatology Clinic and the premises of the Karolinska University Hospital in Solna, as 
well as through the Swedish Rheumatism Association (Reumatikerförbundet). The study 
schematic is shown in Figure 5.  
Within-the-slack Grade I-II Kaltenborn mobilization (154, 156) was carried out for 28 
minutes per participant once/week for four weeks. Four MCP joints (MCP II-V) were each 
treated for three minutes + one minute rest + three minutes. The study included five licensed 
therapists (four naprapaths; one physiotherapist) blinded to diagnosis and ultrasound; six 
physicians for joint assessments blinded to the diagnosis, ultrasound, and treated hand; and an 
ultrasonographer blinded to the diagnosis and treated hand. Hands/wrists were assessed by 
musculoskeletal ultrasound (General Electric LOGIQ EQ; Wauwatosa, WI, USA) with 
previously-reported instrument presets (97, 98, 171). 
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Figure 5. Schematic of the integrative Kaltenborn manual mobilization study in 
rheumatoid arthritis (RA) and hand osteoarthritis (OA) 
Computer randomization stratified for diagnosis was carried out in advance to allocate a hand 
for treatment (within-randomization) for each participant. A diagnosis of RA or hand OA for 
at least six months (m) was required. At baseline (BL), questionnaires were administered to 
obtain participant-reported outcome measures (PROMs); followed by physician hand/wrist 
joint assessment; musculoskeletal ultrasound; and mobilization treatment. The order was 
changed at week two (W2). Upon crossover, the randomized hand (H-rand) was switched to 
control at W3, and the initial control hand (H-control) was switched over to treatment.  
* W3 and W4 followed the same protocol as BL and W2, respectively. Follow-up was 
conducted 1 month after the final treatment at W4, and did not include a treatment session to 
investigate a potential washout effect of the mobilization therapy. 
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4.7 ETHICAL CONSIDERATIONS 
All studies included in this thesis were conducted in accordance to the Declaration of 
Helsinki, where written informed consent was obtained from all participants. The SWEFOT, 
FIN-RACo, and NEO-RACo trials were approved by the regional ethical boards of all 
participating sites (101, 159, 161). Additionally, Papers I-V were individually approved by 
the regional ethics board of Stockholm (EPN, Etikprövningsnämnden).  
For the prospective clinical study, Paper V, careful thought was taken into consideration 
regarding the treatment of the patients with RA, as, to our knowledge, there have been no 
published studies with manual mobilization in RA prior. Within-the-slack Kaltenborn Grade 
I-II mobilization was chosen due to being a safe manual therapy method, while at the same 
time having the ability to reduce pain and relax tense joints without applying the stretching 
forces of Grade III mobilization (154-156). All treatments were carried out by registered and 
licensed providers of physiotherapy or naprapathy in the Rheumatology Clinic of the 
Karolinska University Hospital in Solna, where research physicians were readily available in 
case of any adverse event. Specific exclusion criteria were developed so that the treatment 
would not end up being a risk for the patient: chronic bone damage or soft tissue injuries in 
the hands; acute inflammation within the latest week in any finger joints; any surgery on the 
shoulder, arm, or hand within the latest 3 months; or pregnancy within the latest 3 months.  
 
4.8 STATISTICAL ANALYSES 
Non-parametric Mann-Whitney U tests and Kruskal-Wallis tests with Dunn-Bonferroni 
correction for continuous variables – and Pearson’s χ2 and Fisher’s exact test for proportions 
– were carried out for Papers I-V. Additionally, the Wilcoxon signed rank test and Friedman 
test with Dunn-Bonferroni correction were carried out for Papers III and V; and univariate 
and multivariate binary logistic regression was applied in Paper IV. Two-tailed p values 
<0.050 were considered significant. 
  
 36 
5 RESULTS 
5.1 PAPERS I-II: POPERA IN EARLY RHEUMATOID ARTHRITIS 
5.1.1 Patient characteristics and standard radiographic follow-up 
In Paper I, MTX responders at three months who thus continued on monotherapy were 
generally older than the other SWEFOT patients – significant when compared to patients 
randomized to anti-TNF (Table 3). It was more common for a MTX non-response among 
females; thus, fewer females remained on MTX. The TT arm had a non-significantly lower 
proportion of ACPA/RF-positivity than the anti-TNF arm. There were no differences in 
baseline radiographic scores (all scores are one SHS unit higher, which was required to 
include all patients in the model). 
 
Table 3. Characteristics of eligible patients from the SWEFOT trial for POPeRA 
Outcomes MTX  
(n=117) 
TT  
(n=114) 
Anti-TNF  
(n=112) 
P value 
Age (years) 60 (49, 67)* 56 (43.8, 62.3)  55 (43, 61)* 0.005 
Sex (female) 69 (59%)† 89 (78.1%)† 86 (76.8%)† 0.002 
Duration 5 (3, 7) 5.5 (4, 8) 6 (4, 8) 0.127 
ACPA (+) 67/112 (59.8%) 64/111 (57.7%) 71/102 (69.6%) 0.163 
RF (+) 80/116 (69.0%) 71/113 (62.8%) 78/111 (70.3%) 0.455 
SHS BL 4 (2, 7) 4 (2, 8.3) 4 (2, 8) 0.173 
SHS 12m 5 (2, 10)†† 8 (2.3, 16.8)†† 7 (2, 12.8) 0.043 
SHS 24m 6 (3, 12.5)‡ 11 (2.5, 18)‡ 6.5 (2, 14)‡ <0.050 
 
MTX: methotrexate responders, TT: triple therapy arm, Anti-TNF: anti-tumor necrosis 
factor arm. Outcomes in medians (interquartile range in parentheses): age in years, patient-
reported symptom duration in months before baseline, and the Sharp-van der Heijde Score 
(SHS) at baseline, 12 months (m), and 24m, respectively. Anti-citrullinated protein 
antibody positivity (ACPA) (+) or rheumatoid factor (RF) antibody positivity (+) were 
reported as proportions. Kruskal-Wallis tests were performed with Dunn-Bonferroni 
correction. Post hoc analyses: * MTX > anti-TNF, p=0.005; † MTX < TT and anti-TNF: 
p<0.010; †† MTX (n=107) < TT (n=104): p=0.037; ‡ MTX (n=101) vs. TT (n=109) vs. 
anti-TNF (n=106), post hoc not significant: p=0.070. However, Mann-Whitney U-tests 
comparing MTX vs. TT or anti-TNF vs. TT both were statistically significant: p<0.050. 
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Among absolute radiographic scores, in Paper I, MTX responders had superior 
radiographic outcomes over one and two years to MTX non-responders randomized to TT, 
and MTX non-responders randomized to anti-TNF attained superior two-year outcomes to 
the TT arm (Table 3). In Paper II, there were no baseline differences across the treatment 
arms in FIN-RACo or NEO-RACo, and intensive TT with glucocorticoids in FIN-RACo 
(Combo) was superior to monotherapy over two and five years (Table 4). 
 
Table 4. Characteristics of FIN-RACO and NEO-RACO patients eligible for POPeRA 
Outcomes Combo  
(n=72) 
Single  
(n=72) 
P value¹ Combo + aTNF 
(n=44) 
Combo + PBO 
(n=46) 
P value¹ 
Age (Y)* 48.0  
(39.3, 52.8) 
50.0  
(40.3, 56.8) 
0.184 51.0  
(44.5, 54.0) 
47.5  
(36.0, 55.0) 
0.472 
Sex (F)† 43  
(59.7%) 
49  
(68.1%) 
0.298² 29  
(63.0%) 
32  
(72.7%) 
0.326² 
Duration 
(Months)* 
6.0  
(4.0, 9.8) 
7.0  
(4.0, 10.0) 
0.582 4.0  
(2.0, 5.8) 
4.0  
(3.0, 6.0) 
0.516 
RF  
Positive† 
53  
(73.6%) 
49  
(68.1%) 
0.463² 33  
(71.7%) 
34  
(77.3%) 
0.547² 
Radiograph 
Baseline* 
1.0  
(1.0, 5.8) 
3.0  
(1.0, 8.5) 
0.349 1.0  
(1.0, 3.0) 
1.0  
(1.0, 3.3) 
0.593 
Radiograph 
2 years* 
5.0  
(1.0, 16.5) 
14.5  
(5.0, 23.0) 
0.001 1.0  
(1.0, 4.0) 
2.5  
(1.0, 5.3) 
0.226 
Predicted 
2 years* 
9.0 
(7.0, 22.5) 
10.0 
(6.25, 35.5) 
0.435 13.5 
(7.25, 26.5) 
9.5 
(7.0, 25.75) 
0.194 
Radiograph 
5 years*‡ 
12.0  
(3.3, 27.3) 
25.0  
(11.5, 34.5) 
0.001 2.0  
(1.0, 5.8) 
3.0  
(1.0, 9.0) 
0.302 
Predicted 
5 years*‡ 
21.0 
(13.75, 48.0) 
22.0 
(13.25, 70.5) 
0.445 31.5 
(16.25, 62.5) 
21.5 
(16.0, 61.75) 
0.176 
 
Combo: triple therapy (TT) combination arm (FIN-RACo), Single: monotherapy arm (FIN-
RACo); Combo + aTNF: TT combination + anti-TNF arm (NEO-RACo); Combo + PBO: 
TT combination + placebo arm (NEO-RACo).  
1. Mann-Whitney U test, unless otherwise stated, 2. Pearson’s χ². All the following 
outcomes were reported as the median, followed by the interquartile range in parentheses:  
* Age in years, patient-reported symptom duration in months before baseline (BL), and the 
observed or predicted Larsen (FIN-RACo) or Sharp-van der Heijde (NEO-RACo) 
radiographic score at BL, two-, and five years, respectively. The following were reported as 
proportions: † Sex (% female) and % rheumatoid factor (RF) antibody positive.  
‡ Treatments in all groups became unrestricted after two years. 
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5.1.2 Results from the POPeRA method 
In Paper I, observed radiographic progression was reduced from predicted by 50.1% in TT, 
by 72.3% in anti-TNF, and by 73.9% among MTX responders at year one; and by 87.2% 
(TT), 89.8% (anti-TNF) and 87.8% (MTX) at year two (Figure 6A-C, respectively). There 
was a significantly greater reduction of radiographic progression from predicted at year two 
in the anti-TNF arm when compared either to the MTX or TT arms (n=316, 89.8% vs. 
87.8%, p=0.013; 89.8% vs. 87.2%, p=0.021, respectively; Table 5). Among completers 
who remained on their assigned therapy throughout the entire study, reductions of 56.7% 
(TT) and 76.5% (anti-TNF) from predicted at year one and of 91.0% (TT) and 96.0% (anti-
TNF) from predicted at year two were observed (Table 5). 
 
 
Figure 6. Predicted versus observed radiographic progression in the SWEFOT trial 
Predicted progression (broken line) versus observed progression (solid). Scores are plotted as 
means with standard error for graphical purposes. For more information, see Paper I (100).  
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Table 5. Percent reduction of predicted radiographic progression in SWEFOT 
Time point MTX TT Anti-TNF TT (C) Anti-TNF (C) 
12m 
Median (IQR) 
73.9 (±56.7) 
100 (71, 100) 
50.1 (±103) 
92 (61.8, 100) 
72.3 (±56.4) 
100 (59.3, 100) 
56.7 (±110.8) 
94 (67, 100) 
76.5 (±41.2) 
100 (56.8, 100) 
24m 
Median (IQR) 
87.8* (±27.8) 
100 (88, 100) 
87.2† (±32.2) 
100 (87.5, 100) 
89.8†* (±32.0) 
100 (96, 100) 
91.0 (±3.4) 
100 (92, 100) 
96.0 (±1.8) 
100 (96, 100) 
 
12/24m: 12 or 24 months; MTX: methotrexate responders (12m: n=107, 24m: n=101); TT: 
triple therapy arm (12m: n=104, 24m: n=109); Anti-TNF: anti-tumor necrosis factor arm 
(12m: n=100, 24m: n=106); TT (C).: completers, 12m: n=61, 24m: n=64; Anti-TNF (C): 
completers, 12m: n=74, 24m: n=78. Results are reported as the mean reduction in % with 
standard deviation in parentheses, or the median reduction in percent with the interquartile 
range (IQR) in parentheses; * Anti-TNF vs. MTX: p=0.013, † Anti-TNF vs. TT: p=0.021; 
Mann-Whitney U test. 
 
 
 
In Paper II; in FIN-RACo, intensive TT with glucocorticoids vs. monotherapy resulted in 
superior outcomes in the change from predicted progression over two and five years (mean 
35.7% reduction vs. -32.9%, a worsening from predicted, p=0.001; 34.2% vs. -17.8%, 
p=0.003, n=72, respectively; Figure 7A, Table 6A), and was superior regardless of RF 
positivity (Table 6B). 
 
In NEO-RACo, intensive TT with glucocorticoids + a six-month induction of anti-TNF 
therapy (n=44) led to significantly greater reductions from predicted progression than with 
the addition of placebo (n=46), both at two and five years of follow-up (98.5% vs. 83.4%, 
p=0.005; 92.4% vs. 82.5%, p=0.027, respectively; Figure 7B, Table 6A). However, initial 
anti-TNF add-on treatment was superior only among RF-positive patients when stratifying 
for serostatus (n=34, 33, respectively): two years: 97.4% vs. 80.4%, p=0.009; five years: 
90.2% vs. 80.1%, p=0.030 (Figure 7C, Table 6B). ACPA serostatus was unavailable. 
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Figure 7. Predicted versus observed radiographic progression in the FIN-RACO and 
NEO-RACo trials 
The differences, as a result of therapy, in the percent change of the predicted scores of all 
patients were compared. The mean percent change for all patients within each respective 
therapy is shown; A. (FIN-RACo): Combo: triple therapy (TT) combination arm; Single: 
monotherapy arm; B-C. (NEO-RACo): Combo + aTNF: TT combination + anti-TNF arm; 
Combo + PBO: TT combination + placebo arm; C. Rheumatoid factor (RF)-positive patients. 
The median predicted and observed Larsen (A) or Sharp-van der Heijde (B-C) scores are 
plotted at baseline, two, and five (00, 02, and 05) years. Median scores are plotted 
(interquartile range not in the figure for graphical purposes). Treatment in all groups became 
unrestricted after two years. Predicted slopes might not appear linear all throughout due to 
medians being plotted. For additional information, see Paper II (103). 
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Table 6. Percent reduction of predicted radiographic progression in the  
FIN-RACO and NEO-RACO trials 
A Combo  
(n=72) 
Single  
(n=72) 
P value¹ Combo + aTNF 
(n=44) 
Combo + PBO 
(n=46) 
P value¹ 
2 years 
Median  
(IQR) 
35.7 (±127.4) 
94.2  
(30.8, 100.0) 
-32.9 (±211.6) 
47.8  
(-83.0, 98.4) 
0.001 
 
98.4 (±7.6) 
100.0  
(100.0, 100.0) 
83.4 (±40.6) 
100.0  
(82.6, 100.0) 
0.005 
 
5 years* 
Median  
(IQR) 
34.2 (±127.7) 
80.0  
(21.7, 100.0) 
-17.8 (±175.4) 
47.2  
(-62.5, 86.0) 
0.003 
 
92.4 (±19.8) 
100.0  
(96.3, 100.0) 
82.5 (±41.3) 
98.2  
(75.0, 100.0) 
0.027 
 
 
 Rheumatoid factor (+)  Rheumatoid factor (-)  
B Combo  
(n=53) 
Single  
(n=49) 
P value¹ Combo  
(n=19) 
Single  
(n=23) 
P value¹ 
2 years 
Median  
(IQR) 
21.1 (±143.1) 
88.9  
(-14.3, 100.0) 
-51.2 (±225.7) 
0.0  
(-93.8, 77.5) 
0.003 
 
76.7 (±49.4) 
100.0  
(75.0, 100.0) 
6.2 (±176.1) 
91.7  
(-25.0, 100.0) 
0.114 
 
5 years* 
Median  
(IQR) 
15.9 (±143.3) 
60.0  
(-2.2, 94.8) 
-31.1 (±176.9) 
37.8  
(-86.7, 76.1) 
0.047 
 
85.2 (±35.0) 
100.0  
(80.0, 100.0) 
10.4 (±172.7) 
66.7  
(10.0, 90.3) 
0.002 
 
 Combo + aTNF 
(n=34) 
Combo + PBO 
(n=33) 
P value¹ Combo + aTNF 
(n=10) 
Combo + PBO 
(n=13) 
P value¹ 
2 years 
Median  
(IQR) 
97.4 (±8.0) 
100.0  
(92.6, 100.0) 
80.4 (±46.2) 
97.5  
(82.0, 100.0) 
0.009 
 
101.6 (±5.4) 
100.0  
(100.0, 100.4) 
91.0 (±20.2) 
100.0  
(75.0, 100.0) 
0.343 
 
5 years* 
Median  
(IQR) 
90.2 (±22.0) 
100.0  
(92.9, 100.0) 
80.1 (±46.7) 
96.7  
(73.4, 100.0) 
0.030 
 
99.9 (±2.8) 
100.0  
(98.3, 100.0) 
88.7 (±22.7) 
100.0  
(80.0, 100.0) 
0.648 
 
 
A. All patients in the FIN-RACo and NEO-RACo trials. B. Patients distinguished as 
rheumatoid factor positive (+) or negative (-).  
Combo: triple therapy (TT) combination arm (FIN-RACo); Single: monotherapy arm (FIN-
RACo); Combo + aTNF: TT combination + anti-TNF arm (NEO-RACo); Combo + PBO: 
TT combination + placebo arm, intention-to-treat (NEO-RACo).  
1. Mann-Whitney U test. Results are reported as the mean reduction in percent of the 
predicted Larsen (FIN-RACo) or Sharp-van der Heijde score (NEO-RACo), respectively, at 
two and five years with standard deviation in parentheses, or the median reduction in percent 
with the interquartile range (IQR) in parentheses. Negative values indicate a worsening from 
predicted. * Treatments in all groups became unrestricted after two years. 
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5.2 PAPER III: SERUM SURVIVIN IN EARLY RHEUMATOID ARTHRITIS 
5.2.1 Patient characteristics  
The baseline characteristics of patients with early RA from the SWEFOT trial with available 
serum samples for Paper III are shown in Table 7. Here, no baseline differences were 
observed across survivin status, except that RF positivity was significantly more prevalent 
among the survivin-positive patients, and ACPA positivity was marginally more prevalent. 
 
Table 7. Percent reduction of predicted radiographic progression in the  
FIN-RACO and NEO-RACO trials 
Variables Survivin-positive 
(n=114) 
Survivin-negative  
(n=188) 
P-value 
Age (years) 56.0 (43.0, 62.25) 57.0 (44.0, 67.0) 0.332 
Sex (F) 77 (68%) 143 (76%) 0.107 
Duration 5.0 (4.0, 8.0) 5.0 (4.0, 8.75) 0.905 
RF (+) 91/113 (81%) 108/187 (58%) <0.001 
ACPA (+) 71/107 (66%) 103/183 (56%) 0.091 
VAS-pain 60.0 (45.75, 72.0) 54.0 (39.0, 71.0) 0.269 
VAS-global 60.0 (39.0, 77.0) 58.0 (35.25, 74.0) 0.452 
HAQ 1.25 (0.85, 1.75) 1.0 (0.75, 1.5) 0.079 
TJC 8.0 (5.0, 13.0) 9.5 (6.0, 14.0) 0.134 
SJC 11.0 (6.0, 14.0) 10.0 (7.0, 14.0) 0.692 
ESR 35.0 (21.5, 63.0)** 34.0 (19.25, 50.0) 0.260 
CRP 17.0 (9.0, 54.5)** 18.0 (9.0, 37.0) 0.628 
DAS28 5.78 (5.06, 6.35)** 5.72 (5.02, 6.43) 0.751 
 
Serum levels of survivin >0.45 ng/mL indicated survivin positivity. F, females; RF, 
rheumatoid factor (positive (+)); ACPA, anti-citrullinated protein antibody (+); VAS-pain, 
visual analog scale for pain; VAS-global, patient’s global health; HAQ, health assessment 
questionnaire; TJC/SJC, tender/swollen joint count; ESR, erythrocyte sedimentation rate; 
CRP, C-reactive protein; DAS28, 28 joint-count disease activity score. ** n=113. Medians 
are shown (interquartile range in parentheses). Group comparisons were done by Mann-
Whitney U tests for continuous variables, and by Pearson’s χ² tests for frequencies. 
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5.2.2 Survivin as a theranostic, predictive biomarker 
Regardless of treatment modality, survivin levels decreased significantly at every time point 
over two years (Figure 8A).  
Survivin-positive patients at baseline who responded to MTX monotherapy at month three 
and continued on that treatment had a higher odds of disease re-activation (DAS28 >3.2) at 
year one than if they were survivin-negative (odds ratio (OR) 3.21 (95% confidence interval 
(CI) 1.12-9.24), p=0.032); in addition to failing to improve in DAS28, HAQ, and VAS-global 
health over two years if they still remained positive by three months (see Paper III). 
Survivin-negative MTX responders retained superior low disease activity rates over one year 
(OR 7.81 (95% CI 3.31-20.5, p<0.001) and two years OR 2.51 (95% CI 1.14-5.83, p=0.022) 
than to the MTX non-responders who were randomized to treatment intensification, but not if 
the MTX responders were survivin-positive (Figure 8B). Additionally, survivin-positive 
patients who ever smoked were less likely to have an initial three-month MTX response than 
those who were survivin-negative (OR 1.91 (95% CI 1.01-3.62), p=0.045).  
In survivin-positive patients, randomization to TT led to better improvements in disease 
activity than randomization to MTX + anti-TNF infliximab. Survivin-positive patients on 
anti-TNF had a higher risk of active disease at year two than if they were on TT (OR 3.15 
(95% CI 1.09-9.10), p=0.037) (Figure 8B).  
For additional information on how survivin fluctuations over time affected the clinical ‘core 
set’ measures such as DAS28 and HAQ, see Paper III (109) for more information. 
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Figure 8. Serum survivin in the SWEFOT trial 
A. Changes of serum survivin levels during the SWEFOT trial. Serum levels of survivin were 
measured in 302 patients with available serum samples at baseline, where 114 patients were 
survivin-positive (survivin >0.45 ng/mL, dashed line), and the remaining 188 were negative. 
B. Prevalence of active disease (DAS28 >3.2) among survivin-positive or negative patients in 
SWEFOT, with odds ratios (OR) and 95% confidence intervals (CI) indicated. MTX, 
methotrexate responders; TT, triple therapy arm; anti-TNF, anti-tumor necrosis factor arm. 
A decrease of survivin levels was 
observed at 3, 12, and 24 months after 
antirheumatic treatment. Samples 
available for the analysis are indicated at 
each time point.  
Bolded lines = median levels of the 
survivin-positive at baseline group (open 
circles); and the survivin-negative 
converting to positive group at any time 
point over 24 months (filled rhombi).  
52 (46 %) of the survivin-positive patients 
converted to negative over 24 months. 
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5.3 PAPER IV: OBESITY IN EARLY RHEUMATOID ARTHRITIS 
5.3.1 Patient characteristics 
For all patients from the SWEFOT trial with available BMI (n=260) for Paper IV, the 
characteristics of the patients at baseline who had available follow-up data for the univariate 
and multivariate binary logistic regression analyses did not differ from the original SWEFOT 
dataset (Table 8). Variables at baseline also did not differ across BMI categories, except that 
obese patients were marginally older (Supplementary Material, Paper IV Manuscript). 
 
Table 8. Baseline characteristics of early RA SWEFOT trial patients with available 
body mass index for univariate analyses or the multivariate model did not differ from 
the original SWEFOT trial population 
 
* Missing data were as follows in number, n: body mass index (BMI), 143; smoking status, 
221; rheumatoid factor (RF) status, 4; anti-citrullinated protein antibody (ACPA) status, 25; 
concurrent prednisolone use, 3; and health assessment questionnaire (HAQ), 6.  
   
 
SWEFOT* 
(n=403) 
Univariate** 
(n=215) 
Multivariate† 
(n=154) 
Proportions, n (%)      
   Obese (BMI≥30 kg/m²)   43 (17)   39 (18)   26 (17) 
   Overweight (BMI=25-29.9)   74 (28)   62 (29)   39 (25) 
   Normal weight (BMI<25) 143 (55) 114 (53)   89 (58) 
   Female sex 285 (71) 152 (71) 111 (72) 
   Current smokers   41 (23)   34 (22)   34 (22) 
   RF positive 274 (69) 141 (66)   95 (62) 
   ACPA positive 237 (63) 127 (64)   92 (63) 
   Concurrent prednisolone   58 (14)   28 (13)   19 (13) 
Medians (IQR)      
Age, years   56 (45-64)   56 (44-63)   56 (44-63) 
Symptom duration, months      5 (4-8)      6 (4-8)      6 (4-9) 
DAS28  5.7 (4.9-6.3)  5.9 (5.1-6.5)  5.9 (5.2-6.6) 
    HAQ score  1.1 (0.8-1.5)  1.3 (0.9-1.8)  1.2 (0.8-1.8) 
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** Univariate model, where the 28-joint count disease activity score (DAS28) at 24 months 
and baseline BMI were required. Missing data (n) were as follows: smoking status, 59; RF 
status, 1; ACPA status, 15; concurrent prednisolone use, 3; and HAQ, 4.  
† Multivariate model shown in Table 2 and Figure 3A. Missing data points (n) were as 
follows: RF status, 1; ACPA status, 7; concurrent prednisolone use, 2. 
Abbreviations: RA, rheumatoid arthritis; IQR, interquartile range. Proportions, n (%), were 
compared with Pearson’s χ². Continuous data, medians (IQR), were compared with 
independent samples Mann-Whitney U tests. 
 
Table 9. Baseline predictors of two-year non-remission in the SWEFOT trial 
population with available body mass index, odds ratios and 95% confidence intervals 
Parameters Univariate (n=215)* Univariate (n=154)† Multivariate (n=154)† 
Obesity 4.1 (1.8 - 9.1) 5.4 (1.9 - 15.2) 5.2 (1.8 - 15.2) 
Female sex 2.5 (1.4 - 4.6) 2.4 (1.1 - 4.9) 2.6 (1.1 - 5.8) 
Current smokers 1.8 (0.9 - 4.0) 1.9 (0.9 - 4.0) 2.6 (1.1 - 6.3) 
HAQ 2.0 (1.2 - 3.2) 1.9 (1.1 - 3.2) 1.9 (1.1 - 3.4) 
Age, years 1.0 (1.0 - 1.0) 1.0 (1.0 - 1.0) 1.0 (1.0 - 1.0) 
DAS28 1.7 (1.3 - 2.3) 1.9 (1.3 - 2.7) 1.9 (1.3 - 2.9)‡ 
Tender joints 1.1 (1.0 - 1.1) 1.1 (1.0 - 1.2) 1.1 (1.0 - 1.2)‡ 
 
Risk of not achieving clinical remission (disease activity score, DAS28≥2.6) after two years 
was calculated using uni- and multivariate binary logistic regression (significant findings 
are bolded). Obese- (body mass index (BMI) ≥30 kg/m2) (* n=39; † n=26) were compared 
with non-obese patients (BMI<30, * n=176; † n=128). Additional outcomes assessed: 
female sex; current vs. non-current smokers (* n=156); per-unit increase in health 
assessment questionnaire (HAQ) (* n=211); per-year increase in age; disease activity score 
(DAS28); and tender joints. Non-significant univariate/multivariate predictors included 
concurrent use of prednisolone; patient-reported symptom duration in months before 
baseline; presence of erosions & Sharp-van der Heijde Score; swollen joints; visual analog 
scale for global assessment or pain; erythrocyte sedimentation rate; C-reactive protein; and 
anti-citrullinated protein antibody or rheumatoid factor positivity.  
† Among patients who had available data for all parameters included in the final 
multivariate model (highlighted in grey: obesity, sex, smoking status, DAS28, HAQ, and 
age) (n=154), each predictor was also tested by univariate analysis individually. 
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‡ DAS28 and tender joints were not chosen as predictors in the final model due to 
collinearity. These variables were tested and weighed against their counterparts in a 
multivariate model (DAS28 or tender joints instead of HAQ). The final model provided the 
greatest predictive capacity; predicting non-remission with a classification accuracy rate of 
67.5% versus a null proportional-by-chance accuracy rate of 50%. 
 
 
 
5.3.2 Obesity as a predictor of worse clinical outcome measures  
Upon diagnosis of early RA, despite no baseline differences, obesity was associated with 
worse ‘core set’ clinical outcomes over two years (DAS28, HAQ, and VAS-pain; year two: 
obese vs. normal: p<0.001; obese vs. overweight: p<0.050) (Figure 9).  
Obese- compared to non-obese patients had independently greater odds of non-remission at 
year two (adjusted OR 5.2, 95% CI 1.8-15.2). Other independent predictors were female 
sex (adjusted OR 2.6, 95% CI 1.1-5.8), current smoking (adjusted OR 2.6, 95% CI 1.1-6.3), 
and HAQ (per-unit increase, adjusted OR 1.9, 95% CI 1.1-3.4) (Figure 10).  
The pattern was similar among MTX responders, and among MTX non-responders 
randomized at three months to TT, although significance was not found among obese 
patients randomized to anti-TNF infliximab (Figure 11). ACPA/RF positivity did not 
distinguish differences for these findings, and obesity had no independent association to 
radiographic progression (Paper IV Manuscript). 
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Figure 9. Changes in clinical outcome measures over two years in the SWEFOT trial by 
baseline body mass index (BMI) categories  
Mann-Whitney U tests were performed for all calculations. Medians and interquartile range 
are plotted for each BMI category. A-D: DAS28, HAQ, VAS-pain, and ESR, respectively, 
are plotted at baseline (BL); and at 3, 6, 9, 12, 18, and 24 months (m). 
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Figure 10. Independent baseline predictors of two-year non-remission in the SWEFOT 
trial 
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Figure 11. Changes in clinical disease activity over two years in SWEFOT trial 
participants randomized to triple therapy or anti-TNF with available baseline body 
mass index (BMI) categories 
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Figure 10. Legend 
A: Adjusted odds ratios (OR) with 95% confidence intervals (CI) for significant predictors in 
a binary logistic multivariate analysis of non-remission. NS: not significant. Additional 
information can be found in Table 9. 
B: Risk matrices showing the likelihood (%) of non-remission with different combinations of 
predictors presented in A. 
Body mass index (BMI) and two-year disease activity was available for 215 out of originally 
403 Swedish pharmacotherapy (SWEFOT) trial participants. Of these, the health assessment 
questionnaire (HAQ) was available for 211 patients; and smoking habits for 156 patients. Of 
those with HAQ and smoking habits (n=154), 26 were obese; 34, current smokers; 22, 
methotrexate (MTX) responders; 65, randomized to triple therapy (TT); 67, randomized to 
MTX+tumor necrosis factor inhibitor (anti-TNF) infliximab. 
 
Figure 11. Legend 
Patients not achieving low disease activity (DAS28<3.2) at the 3-month (m) follow-up visit 
were randomized, and the European League Against Rheumatism (EULAR) good response at 
the two-year follow-up was calculated using randomization at 3m as the baseline value 
(obese versus normal weight). Individual timepoints with DAS28 over two years are plotted 
with medians and interquartile range. Included among all patients (A) is the combination of 
the two randomized groups, triple therapy (TT) (B, n=94) or anti-tumor necrosis factor (TNF) 
(C, n=91). Responders to methotrexate (MTX) (DAS28≤3.2) continued on monotherapy and 
are not included due to non-randomization. Sample size (n) for normal weight, overweight, 
and obese in A: 103, 48, 32; B: 52, 22, 20; and C: 53, 26, 12, respectively.  
Obese versus normal- or overweight: * p<0.050; ** p≤0.002. 
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5.4 PAPER V: INTEGRATIVE MEDICINE IN RHEUMATOID ARTHRITIS 
5.4.1 Participant characteristics 
Among baseline characteristics and primary outcome measures, the research participants with 
RA did not differ from the hand OA participants, except that those with hand OA were older 
and started with numerically more overall VAS-pain (Table 10).  
 
Table 10. Baseline parameters of research participants with rheumatoid arthritis or 
osteoarthritis in the randomized Kaltenborn manual mobilization crossover study 
 
RA (n=12) OA (n=8) 
Proportions, n (%)     
   Female sex 8 (67) 7 (88) 
   Randomized hand (R) 7 (58) 3 (38) 
   Dominant hand (R) 10 (83) 6 (75) 
   Ever-smokers 7 (58) 5 (63) 
   ACPA/RF positive 4/8 (50) - 
Medians (IQR) 
  
Age 61 (49.5 - 63.8)* 69.5 (66.5 - 73)* 
Disease duration (Y) 6 (1.1 - 6) 7 (4.3 - 19.3) 
 Outcomes by hand H-rand H-control H-rand H-control 
Hand pain MCP 1.5 (0 - 43.9) 7.3 (0 - 55.1)     10 (0 - 37.9)     15 (6.3 - 50.4) 
Hand pain region 3.3 (0 - 49.1) 1.9 (0 - 40.8)  12.5 (0 - 46.9)     25 (6.3 - 50) 
Swollen joints‡   1.5 (0 - 3)      1 (0 - 3.8)    1.5 (1 - 2)       1 (0 - 2) 
    Tender joints‡   4.5 (2.3 - 7)      4 (2.3 - 5)     4 (1.5 - 13)       5 (2.5 - 14.8) 
Q-Doppler, MCP† 
Q-Doppler, region† 
     0 (0 - 2) 
   0 (0 - 15.9) 
   0 (0 - 22.2) 
     0 (0 - 2.2) 
- 
- 
- 
- 
Synovial fluid, MCP† 
Synovial fluid, region† 
     0 (0 - 7.2) 
     0 (0 - 3.4) 
     0 (0 - 2.5) 
     0 (0 - 2.1) 
- 
- 
- 
- 
Joint space, MCP 
Joint space, region 
  1.1 (1 - 1.3) 
  0.9 (0.7 - 1.1) 
  1.1 (1 - 1.3) 
 0.9 (0.7 - 1.1) 
    1 (0.9 - 1.1) 
   0.8 (0.6 - 1) 
      1 (0.9 - 1.1) 
   0.8 (0.7 - 1) 
VAS-pain 33.7 (15.1 - 71.3) 63.8 (42.3 - 85.9) 
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RA: Twelve participants with rheumatoid arthritis. OA: Eight participants with hand 
osteoarthritis (serostatus and acute-phase reactants unavailable).  
Abbreviations and parameter explanations: randomization: proportion of right hand, R, vs. left 
hand randomized; dominant hand: proportion right, R vs. left; ever-smokers: current + past-
smokers vs. never-smokers; ACPA/RF, anti-citrullinated protein antibody and/or rheumatoid 
factor positive; IQR, interquartile range; Y, years; H-rand, randomized hand; H-control, control 
hand; Hand pain, participant-reported pain intensity by visual analog scale (VAS) in the 
metacarpophalangeal, MCP joints II-V before treatment, followed by regional pain intensity 
among hand joints, Region: MCP II-V + proximal- and distal interphalangeal, PIP & DIP, joints 
II-III, respectively; Quantitative (Q) color Doppler musculoskeletal ultrasound (MSUS) activity 
indicates the absolute score (%) of hyperemia/blood flow activity within an inflamed joint; 
synovial fluid (area of synovial hypertrophy and fluid effusion by MSUS, mm2); joint space 
(radiographic distance between the MCP and/or interphalangeal bone space, mm, measured by 
MSUS); VAS-pain (overall). Exploratory measures can be found in the Paper V Manuscript.  
† Due to a limited amount of participants expressing color Doppler signal or synovial 
hypertrophy and/or fluid effusion by MSUS, medians are shown with 5th - 95th percentiles in 
parentheses. The participants with hand OA had negligible signals or fluid.  
‡ Swollen/tender joints were instead based on a modified physician’s evaluation of the hands and 
wrists of the participants, including all DIPs/PIPs but excluding the shoulders, elbows, and 
knees. Between-group differences (RA versus OA): * Statistical significance: age, p=0.002 
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5.4.2 Subjective and objective improvements from mobilization therapy 
Among the participants with RA, systemic subjective and objective improvements were 
observed. Both the initially-randomized- and contralateral hand improved significantly from 
baseline-crossover-follow-up at two months (pain outcomes/Doppler signal, p<0.050; 
synovial fluid/MCP joint space, p≤0.001) (Figures 12-13). The proportion of MCP joints that 
were synovitis-positive (exhibiting Doppler activity and synovial hypertrophy/effusion) 
decreased significantly from baseline to follow-up (randomized hand MCP joints: 20.8% 
(10/48) vs. 8.3% (4/48); initial control hand MCP joints: 18.8% (9/48) vs. 10.4% (5/48); 
p≤0.025, respectively). The change from effusion presence to null effusion from baseline to 
follow-up for the hand region was also significant (randomized hand joints: 20.8% (20/96) 
vs. 7.3% (7/96); initial control hand joints: 18.8% (18/96) vs. 8.3% (8/96); p≤0.004, 
respectively). The participants in the hand OA arm had negligible Doppler activity or 
effusion.  
From baseline-crossover-follow-up, highly significant increases in MCP joint space were 
observed (p≤0.001); namely, joint space from BL-Follow-up increased from 1.1 to 1.4 mm 
(median 21.2% increase [IQR 10.3-32.8%]) (Figure 13). Figure 14 shows improvements in 
MCP joint space and synovial fluid (A-B), and Doppler activity (C-D) over two months.  
In the participants with hand OA, they started out with less MCP joint space and a large 
increase was observed from baseline-crossover-follow-up, from 1.0 to 1.4 mm (26.7% [23.1-
35.2%]). Pain in addition to MCP joint space improved in hand OA, and the specific results 
from these participants can be found in the Paper V Manuscript (Supplementary Material). 
There were no dropouts or reported adverse events in either RA or hand OA.  
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Figure 12. Hand visual analog scale for pain among participants with rheumatoid 
arthritis treated with Kaltenborn manual mobilization 
A. Hand-pain composite score by visual analog scale (VAS), medians and interquartile range, 
among metacarpophalangeal (MCP) joints II-V that were treated with Kaltenborn 
mobilization either from baseline to week two (BL-W2) (randomized hand, H-rand) or from 
W3-W4 (initial control hand, H-control), n=48 vs. n=48, respectively; B. Regional hand-pain 
composite score among MCPs II-V in addition to the pain scores from the untreated 
proximal- and distal interphalangeal (PIP/DIP) joints II-III, n=96, H-rand vs. n=96, H-
control, respectively. Dashed line indicates crossover at W3 (H-rand becomes control; H-
control is now treated directly after the W3 assessment). 
Follow-up: one month after the last treatment at W4; Pre-Tx (BL and W3), VAS-pain directly 
before treatment with mobilization; Post-Tx (W2 and W4), VAS-pain directly after treatment 
with mobilization. Medians and interquartile range are plotted. H-rand vs. H-control: No 
significant between-group differences. * Statistical significance (p<0.050), ** p≤0.001.  
 56 
BL vs. W2: A. H-rand, p=0.046, H-control, p=0.032; B. p=0.002, respectively. BL vs. W3: 
A. H-rand, p=0.018, H-control, p=0.009; B. p<0.001, respectively. 
Crossover: W3 vs. W4: A. H-control (treated), p=0.018. BL vs. W4 (not plotted in figure): A.  
H-rand, p=0.007, H-control, p=0.002; B. H-rand/control, p<0.001, respectively. BL vs. 
Follow-up: A. H-rand, p=0.029, H-control, p=0.010, B. H-rand, p=0.009, H-control, p=0.025. 
 
Figure 13. Metacarpophalangeal joint space among participants with rheumatoid 
arthritis treated with Kaltenborn manual mobilization 
Metacarpophalangeal (MCP) joint space (between tip of phalanges to tip of metacarpus) 
among MCP joints II-V that were treated with Kaltenborn mobilization either from baseline 
to week two (BL-W2) (randomized hand, H-rand) or from W3-W4 (initial control hand, H-
control), n=48 vs. n=48, respectively. Foll-up: one month follow-up after the last treatment at 
W4; Pre-Tx (BL and W3), joint space directly before treatment with mobilization; Post-Tx 
(W2 and W4), joint space directly after mobilization treatment. Medians and interquartile 
range are plotted in addition to each individual value. H-rand vs. H-control: No significant 
between-group differences. * Statistical significance (p<0.050), ** p≤0.001. BL vs. W2: H-
rand, p=0.018, H-control, p=0.003; BL vs. W3: H-rand, p=0.001, H-control, p<0.001.  
Crossover: W3 vs. W4: H-rand (untreated), p=0.002, H-control (treated), p<0.001. BL vs. 
W4 (not plotted in figure) or BL vs. Follow-up: H-rand/control, p<0.001, respectively.  
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Figure 14. Changes in metacarpophalangeal joint space, synovial fluid, and Doppler 
activity in rheumatoid arthritis over 2 months with Kaltenborn manual mobilization 
The following images are from two participants (P1, A-B; and P2, C-D, respectively) with 
rheumatoid arthritis included in this study who gave consent to publication of their 
musculoskeletal ultrasound images. A-B. Metacarpophalangeal joint space of P1 at baseline 
(BL, 1.5 mm) and follow-up one month after the final treatment at W4 (2.0 mm), 
respectively; including presence of synovial fluid at BL (0.8 mm2), which is gone by follow-
up. C-D. Presence of active Doppler quantification of P2 at BL (Ratio, 15.9%; Max: 30.3%), 
which is virtually gone by follow-up (Ratio: 0%; Max: 1.3%), respectively. 
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6 DISCUSSION 
The overall aim of this thesis was to evaluate an approach of personalized integrative 
medicine. First, the state of established knowledge pertaining to RA was reviewed, including 
its pathogenesis, clinical course, classification, and treatment paradigms. Next, imaging 
modalities, biomarkers, environmental and lifestyle risk factors, and integrative medicine in 
RA were identified. An investigation was then carried out for predicting the disease course of 
RA – with the simulation provided through POPeRA and radiography (imaging) (Papers I-
II); the theranostic capability of serum survivin (biomarkers) (Paper III); and the clinical 
relevance of BMI and lifestyle factors (risk factors) for disease outcome (Paper IV) – as well 
as monitoring RA outcome with the applied approach of integrating established manual 
therapy with the standard of care (integrative medicine) (Paper V). 
 
6.1 SUMMARY AND INTERPRETATION OF MAIN RESULTS 
6.1.1 Papers I-II: The POPeRA method 
In Papers I-II, the simulation of predicted vs. observed radiographic progression through 
POPeRA identified the value of creating a true control reference point – which is otherwise 
impossible to observe in RA due to the good standard of care in allopathic medicine and 
rheumatology to treat a newly-diagnosed patient with early RA immediately. With POPeRA, 
we can now emulate how patients diagnosed with RA would progress if they had not received 
DMARDs; and can thus compare the relative radiographic efficacy of various treatments with 
more sensitivity than by comparing radiographic scores – especially today since radiographic 
differences are more difficult to observe across treatments due to the successful standards of 
the modern T2T approach (85, 88) and treating within the ‘window of opportunity’ (13-16).  
In Paper I, significant reductions were observed from predicted radiographic progression 
regardless of the treatment modality. However, the original findings from the randomized 
SWEFOT trial with POPeRA were confirmed – where it was found that after a three-month 
MTX non-response, randomization to anti-TNF+MTX was radiographically superior to TT at 
year two (and clinically superior by a EULAR good response at year one) (101, 102). We 
demonstrated through POPeRA that anti-TNF therapy was not only superior by the 
radiographic SHS score but was also able to prevent more radiographic progression than TT. 
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In Paper II, significant reductions from predicted radiographic progression were also 
observed with POPeRA regardless of the DMARD being utilized. The original results of the 
randomized FIN-RACo trial were confirmed: that intensive TT with glucocorticoids was 
radiographically superior to monotherapy with SSZ or MTX over two and five years, 
regardless of RF status (159, 160). Upon application of POPeRA in the randomized NEO-
RACo trial, additional treatment intensification to the same TT modality with an induction of 
six months of anti-TNF infliximab therapy provided additional radiographic benefits, not 
only over two years (161), but also over five years compared to intensive TT + placebo – 
which was not seen in the original five-year follow-up publication by traditional radiographic 
score analysis (162). However, this beneficial effect was observed exclusively among RF-
positive patients upon stratification by serostatus. POPeRA was therefore able to further 
inform the NEO-RACo results by identifying a subgroup of patients with early RA who 
could particularly benefit from just receiving a short-term induction of anti-TNF therapy. 
 
6.1.2 Paper III: Serum survivin in early rheumatoid arthritis 
The importance of serum survivin in early RA was investigated and established with an in-
depth post hoc analysis carried out in the SWEFOT trial. Considering the rarity of elevated 
survivin presence in the serum of healthy individuals (<5%) (105, 170), survivin positivity 
was a rather prevalent subset in early RA – accounting for one third of all SWEFOT patients. 
The results confirm that survivin positivity at baseline generally predicts worse one- or two-
year clinical outcomes, particularly among initial MTX responders who continue on 
monotherapy and have later disease reactivation; and among patients randomized to the add-
on of anti-TNF therapy. The risks of active disease (DAS28 >3.2) that survivin-positivity was 
associated with, however, appeared to at least be partly abrogated upon randomization to TT 
– so much so that clinical outcomes were more favorable among TT vs. anti-TNF at year two. 
It was also found that survivin-positive ever-smokers had a higher chance of initial MTX 
non-response at three months – thus backing up the established knowledge of smoking as a 
risk factor of worse outcome in RA (115, 172). 
Complementing the predictive baseline findings, in addition to disease reactivation by 
DAS28, continued survivin positivity up to three months was associated with long-term 
functional deterioration by HAQ and worse overall health by VAS-global over two years 
despite initial response to MTX. These findings inform T2T-steered treatment and 
observational studies that had previously identified the importance of the initial MTX 
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response (172-176) that survivin is a clinically-useful biomarker that can be included to 
predict a maintained long-term MTX response. These results also provide a potential 
alternative treatment pathway through TT upon survivin-associated MTX failure. If 
additional studies do not confirm our results with TT being an effective approach to survivin 
positivity, perhaps anti-survivin treatments now being tested in cancer (as survivin is 
expressed in a plethora of cancer types) could one day be incorporated into RA practice (177-
181). Synovial hyperplastic growth in RA – likely sustained by survivin – is not unlike 
cancer, and the success of TT in SWEFOT for survivin positivity could be due to the 
synergistic effects of HCQ, which has been demonstrated (in addition to its originator, 
chloroquine) to improve cancer patient responsiveness to both conventional anti-cancer 
therapies like MTX as well as novel agents by directly inhibiting autophagy (182, 183) – 
which is a key component in sustaining synovial hyperplasia in RA (184). 
 
6.1.3 Paper IV: Obesity in early rheumatoid arthritis 
In RA, obesity has been associated with worse clinical-, but not radiographic outcomes (133, 
134). However, there are only limited data from early disease onset and from randomized 
clinical trials in the context of specific treatments. Furthermore, it is not clear whether known 
predictors of outcome might explain this association.  
In this early RA SWEFOT trial reflecting today’s standard treatment (MTX with add-on of 
anti-TNF or triple therapy in non-responders), a clear dose-response relationship with BMI 
categories and clinical disease activity was observed over two years. A consistent dose-
response in all individual components of the DAS28 was observed, except for significance 
not being reached with the swollen joint count. Obesity strongly lowered the chance of 
attaining good clinical outcomes; including remission. Namely, obese patients at baseline – 
despite no differences in disease activity – had over a five-times higher independent odds of 
not reaching remission at year two compared to non-obese patients. Other independent 
predictors of non-remission included female sex, current smoking, and functional 
impairment. When stratifying by individual treatments, the same pattern was observed for 
MTX responders and the TT arm; however, obese vs. non-obese patients assigned to anti-
TNF did not have significantly worse disease activity over two years. The results were 
independent of ACPA/RF, and obese patients had numerically but non-independently less 
radiographic progression.  
  61 
These findings demonstrate that the likelihood of remission can be predicted using measures 
that are easily-available in the clinic at diagnosis, and highlight the importance of considering 
lifestyle modifications as a new treatment paradigm in the care of patients with RA. 
Potential mechanisms for fat mass to be involved with inflammation in RA naturally include 
the chronic state of inflammation caused by adiposity, with increased Mɸ 
activation/infiltration in white adipose tissue from free fatty acids (185, 186) – thus leading to 
increased TNF and IL-6 secretion. Two potential biomarkers that could explain the discrepant 
findings between better clinical outcomes but more progression among lean patients with RA, 
and more inflammation and less erosions among obese patients with RA, are adiponectin and 
leptin, respectively. Adiponectin is under normal conditions an anti-inflammatory biomarker, 
yet it appears to play an erosive role in autoimmunity. It is elevated with normal BMI and has 
been shown to be associated with erosive disease in RA (163, 187, 188). Leptin, on the other 
hand, is directly proportional to BMI, and may explain the clinically apparent inflammatory-
associated phenotype of RA (163, 189, 190). More investigations on these two biomarkers 
are warranted. 
 
6.1.4 Paper V: Integrative medicine in rheumatoid arthritis 
The integrative randomized Kaltenborn mobilization crossover pilot study – carried out over 
a total time period of two years from start to finish – was the first of its kind, where, to our 
knowledge, no prior studies had ever been performed pertaining to mobilization in RA. The 
purpose was to test the clinical feasibility, safety, and effectiveness of Kaltenborn manual 
mobilization in RA. The aims were met by the results, in that we observed significant 
reductions in overall pain, hand pain (MCPs or the hand region); hand joint Doppler activity 
and synovial fluid; as well as highly-significant improvements in MCP joint space over two 
months. Equivalent improvements in pain and joint space were observed in the clinical 
comparator group with hand OA. Importantly, there were no study dropouts or reported 
adverse events in either RA or hand OA. While all the improvements were systemic 
regardless of which hand was treated, a placebo effect or regression to the mean cannot be 
disregarded. However, with the objective joint improvements in either hand as observed 
through ultrasound – regardless of which hand was treated – it cannot be ruled out that 
mobilization may affect both hands through a potential systemic stimulatory effect on the 
central nervous system. Thus, Kaltenborn within-the-slack Grade I-II mobilization (154, 156) 
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was found to be a feasible, safe, and effective approach for treating RA patients with 
refractory pain. 
Despite Kaltenborn mobilization being a worldwide modality used by multiple manual 
therapy professions for treating joint pain and improving mobility, the scientific literature of 
its use beyond mobilization of the shoulder and elbow joints is limited (155). Therefore, we 
had first conducted an initial pilot study of five women with RA to preliminary determine its 
safety and effectiveness with three extended mobilization sessions within one week, and 
observed significant reductions in pain and Doppler quantification (157, 158). In light of 
these results, the inception was made for the current longer-term integrative mobilization 
study. The initial pilot study had included participants with active Doppler (mean 52% 
activity) and a 21% mean reduction in hyperemia was observed. However, the current study 
had recruited patients with minimal Doppler activity despite experiencing daily bilateral pain 
in the hands (median 0%; maximum 32.1% activity). Despite this, we observed a significant 
reduction in the proportion of hyperemic MCP joints over two months (8.4-12%, depending 
on the hand).  
Though subjective or objective improvements were indistinguishable, regardless of which 
hand was treated, there is evidence pointing to a potential systemic effect of mobilization. For 
example, mobilizing one hand in carpometacarpal (CMC) OA has been shown to have 
systemic improvements in the untreated contralateral hand, including pain and grip strength 
(191-193). Strength or range of motion in exercise has also been shown to affect the untreated 
contralateral side of the body (194-199); as well as pain analgesia with transcutaneous 
electrical nerve stimulation (200-202). Additionally, a vacuum phenomenon followed by an 
increase in MCP joint space has previously been reported as a result of mobilization in 
healthy individuals (203), which could be an underlying mechanism to the displacement or 
clearance of excessive synovial fluid observed in our study. Additional mechanisms of action 
may also include reduction of TNF and IL-6, as has been suggested through massage therapy 
research (204).  
Altogether, Kaltenborn manual mobilization of the hands appears both feasible and safe as a 
clinically integrative method to potentially bring into the practice of rheumatology, and larger 
randomized controlled studies to confirm or refute these results are warranted.   
  63 
6.2 METHODOLOGICAL CONSIDERATIONS 
6.2.1 Strengths and limitations 
6.2.1.1 Papers I-II 
The strengths of the POPeRA method are that it is a simple technique to adapt and can be 
utilized practically by any rheumatology clinic. The only requirements are: 1) the symptom 
duration reported by the patient before diagnosis, which is date of first symptom onset in 
months; 2) a baseline radiograph and radiographic score such as SHS or Larsen; and 3) an 
additional radiograph/score at least at one point of follow-up. The first application of the 
technique by Wick et al. was verified with the results of subsequent non-responders to 
DMARD therapy (99), who had minimal reductions from predicted progression; also verified 
as a sensitivity analysis in Paper I (100). Through the confirmation that POPeRA provided 
of all results in several randomized clinical trials (SWEFOT, FIN-RACo, NEO-RACo), in 
addition to providing new insight in identifying responders to targeted therapy (Paper II, RF-
positive patients with anti-TNF induction), its future use in other datasets is encouraged – as 
conventional radiographic analysis cannot simulate how patients may progress if untreated. 
Before POPeRA, a similar ‘benchmark’ method was published in a brief report where the 
authors argued against comparing progression rates of patients with early RA (205), however, 
their approach did not take into consideration the important ingredient of patient-reported 
symptom duration before diagnosis. Instead, disease duration from diagnosis until inclusion 
in a trial was utilized. We have confirmed that POPeRA is a valid approach in early RA when 
based on the patient’s self-reported symptom duration before diagnosis (diagnosis was the 
same as baseline inclusion in our context). Potential methodological weaknesses include 
disease duration errors (recall bias from the patient), which requires a reliable patient-
physician relationship to prevent. Additionally, POPeRA may overestimate progression as it 
is not entirely linear among individuals (99, 206, 207), yet relatively accurate in the context 
of groups (208). To further improve the POPeRA simulation, an equation could be 
incorporated which would be sensitive to the trend that the rate of radiographic damage 
lessens after one year. Though there were fewer women among the MTX responders in 
Paper I as well as a higher age compared to the randomized arms, the radiographic damage 
at baseline was the same; additionally, it has previously been reported that neither sex nor age 
played significant roles concerning progression in early RA (209), despite older age having 
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the potential chance to be associated with marginally higher SHS due to concurrent hand 
osteoarthritis (210).  
While the POPeRA findings from Paper II demonstrated considerable numerical mean 
differences (e.g. 10% favorable difference over five years in prevention of radiographic 
progression with anti-TNF induction, Figure 7), the results of Paper I at two years might not 
appear so numerically different for anti-TNF arm vs. TT (Table 5), especially when taking 
into consideration the costs of anti-TNF over TT (211-213), in addition to no greater 
prevention of sick leave or disability pension over several years (214). It could thus be argued 
that anti-TNF should only be considered upon TT failure as a treatment option. However, in 
addition to the findings reaching statistical significance, first quartile comparisons revealed a 
percentage reduction difference of 8.5% in favor of anti-TNF. It is important to stress that 
each physician should decide the clinical value of each DMARD and to take a good amount 
of thought into the correct treatment option for their patients.  
Finally, in Paper II, radiographic progression was more similar to the predicted score in the 
FIN-RACo dataset. This could be due to wider inclusion criterion: maximum-allowed 
symptom duration of 24 months, instead of 12 for NEO-RACo. Utilizing the Larsen score 
may also have limitations in generating a lower slope. As a result, it appeared as if patients on 
monotherapy had worsened mean changes than predicted. The median change, however, was 
a 47% improvement at two and five years in these patients. For future POPeRA analyses, 
inclusion criteria of a maximum of 12 months of symptom duration should thus be used, and 
most ideally with SHS.  
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6.2.1.2 Paper III 
The strengths of this study were that a large proportion of samples were available, 
particularly at baseline and 3 months; and they were all utilized to create an in-depth analysis 
of survivin in the clinical setting of early RA. We had robust statistical results and per 
protocol sensitivity analyses that confirmed our main findings. Additionally, our predictive 
baseline findings were confirmed by creating survivin follow-up groups among all individual 
therapies. 
Factors that could have influenced the results include possible drug cytotoxicity, which could 
have influenced survivin level release; however, the small proportion of patients who had 
fluctuating survivin status over several time points were excluded from analysis. A combined 
ACPA/RF and survivin analysis could have further strengthened the findings due to their 
coexistence in severe RA (107, 215); however, autoantibody status is often associated with a 
strong anti-TNF response (216) – which was the opposite for survivin-positive patients in 
SWEFOT. Though autoantibody status in the SWEFOT trial was not a predictor of ‘core set’ 
clinical outcomes, which were the outcome measures utilized for this post hoc study, future 
studies directed in testing survivin clinically as a theranostic marker should nonetheless 
consider testing survivin’s independent predictive value in relation to ACPA/RF. Thus far, no 
interfering cross-reactions have been found when testing survivin against ACPA/RF (107).  
Finally, a somewhat limited final number of patients within TT and anti-TNF for survivin 
follow-up stresses the importance of additional studies to be carried out to investigate TT as 
an option for treating survivin-positive patients and to determine the potential mechanism 
behind its success – such as the potential impact of HCQ and/or SSZ, and whether the 
effectiveness may be unique to these drugs alone and/or if it is their combination that 
enhances the efficacy of MTX against inflammation made resistant through survivin.  
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6.2.1.3 Paper IV 
The strengths of this study were that, in the randomized clinical setting of SWEFOT, despite 
no baseline differences, BMI categories were consistently shown to have a significant dose-
response relationship with clinical disease activity in the majority of follow-up occasions. 
Obese patients had the poorest clinical outcomes, including disease activity, pain, and 
functional disability. Advanced multivariate binary logistic regression was carried out to rule 
out potential confounding of the results, and obesity was found to be a strong independent 
predictor of non-remission over two years. 
A limitation in this study was that SWEFOT wasn’t specifically powered to test for post hoc 
analyses including BMI or smoking, particularly among individual therapies. Thus, several 
patients did not have such data, particularly in follow-up visits. Secondly, the size of the 
individual treatment groups does not allow a definite conclusion on our results, particularly 
pertaining to obese patients having better anti-TNF responses than with TT. It could be that 
the infliximab responses were attributable to the fact that obese patients in fact received more 
of the drug due to their weight; however, this was not seen in other studies in RA involving 
elevated BMI and infliximab in different contexts (163, 217, 218).  
Additional studies investigating conventional vs. biological agent response with BMI in early 
RA (obesity in particular) are needed, including weight-adjusted infliximab vs. the other non-
adjusted anti-TNF agents, as well as dose escalation strategies with conventional therapy. In 
SWEFOT, for example, only SSZ could be elevated from 1000 to 1500mg twice daily in TT. 
It could be possible that the obese patients treated with MTX and TT required even higher 
doses to have effective responses, as it has been shown that MTX polyglutamates have a 
strong inverse association to BMI (219), which ought to be taken into consideration for future 
study designs. 
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6.2.1.4 Paper V 
The strengths of this study of integrative manual therapy are that subjective improvements of 
pain relief have been quantified by objective improvements in the joints. Additionally, due to 
the strict design of the study, several biases have been controlled for with the following setup: 
at least two different manual therapists per participant, and two per hand, who were blinded 
to diagnosis, outcomes, and physician/ultrasound evaluation; at least two different physicians 
per participant, who were blinded to diagnosis, the treated hand, outcomes, and ultrasound; 
and an ultrasonographer (blinded as physicians) who randomly selected participant 
ultrasound images for analysis together with the study coordinator (blinded to the random 
selection and thus the treated hand) – who both analyzed the ultrasound images together with 
the ultrasonographic reference atlas by Hammer et al. (220), where disputes were resolved by 
consensus. Additionally, the ultrasonographer conservatively analyzed joint space for all 
follow-up visits with slight undermeasurement. An image-measurement repeat pilot exercise 
was also performed for the first participant’s images and was concluded with minimal 
measurement error (<5%). Lastly, the study yielded clinically relevant results that could be 
incorporated as an integrative medicine in practice; with a limited amount of sessions over 
four weeks, carried out once a week for 28 minutes each. Importantly, the observed 
improvements in RA were sustainable and did not have a one-month wash-out effect. 
Limitations of this study include the monocentric design and small patient sample size, 
although a considerable amount of individual joints were analyzed for primary outcomes 
(n=320). Participants could have also attempted to mobilize their own hands; however, they 
were specifically instructed not to do so. Background medication could also have interfered 
with the results; however, participants were instructed to not take their medication during the 
day before- or the day of mobilization (if possible). Methodology that could be taken into 
consideration for future studies include considering a larger patient sample size; a longer 
follow-up time and duration before crossover; and to include a standard of care RA reference 
control group receiving non-therapeutic ultrasound, as was done in CMC OA (191-193, 221), 
to further test the possibility of a placebo vs. systemic mobilization-induced therapeutic 
effect. Additionally, a larger proportion of participants with active joint inflammation should 
be included. Finally, the synergistic treatment effect that was observed ought to be evaluated 
physiologically with more mechanistic studies; and qualitatively by studies involving 
interviews or focus group discussions to investigate perceptions and experiences of treatment 
effects and their relations to the intervention itself and/or the totality of care including the 
interaction with the providers of care. 
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6.2.2 Statistical analyses 
Conservative non-parametric statistical analyses as indicated under Materials and Methods 
were applied so that a consistent approach could be demonstrated across Papers I-V; and so 
as to prevent type I errors – as much of the data did not have parametric distributions, and 
several subgroup analyses ended up having small sample sizes.  
 
6.2.2.1 Sensitivity analyses 
Several sensitivity analyses were applied so as to confirm the main findings of Papers I-V.  
In Papers I-II, various sensitivity analyses were carried out, e.g. to test for different subsets 
of patients. For example, the final sensitivity analysis did not utilize imputation and included 
patients who only had a positive radiographic score at baseline. All sensitivity analyses 
confirmed the main findings. 
Upon conducting Paper II, an important factor that was decided to control for was serostatus 
in the POPeRA model as a sensitivity analysis, which was not included in the methodology of 
Paper I as its purpose was only to confirm the original SWEFOT results. Upon carrying out 
this analysis, we discovered that the association that was driving the more favorable 
reductions from predicted progression with six-month anti-TNF induction was among the 
RF-positive patients in particular. ACPA – which is an established potential predictor of 
radiographic progression (222-226) – was not available in the FIN-RACo and NEO-RACo 
datasets. In light of these results with RF, additional studies involving POPeRA ought to 
include both RF and ACPA as sensitivity analyses.  
In Papers I, III, and IV, per protocol (completers who remained true to their assigned drug) 
and last observation carried forward sensitivity analyses were carried out to test the main 
analyses, all of which confirmed the original results.  
In Paper V, sensitivity analyses that were carried out were all analyses for the clinical 
comparator group with hand OA, who had equivalent improvements in pain and joint space 
as to the participants with RA. Doppler activity and synovial fluid was negligible in the OA 
participants.  
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7 CONCLUSIONS 
In Papers I-II, it was demonstrated how the novel POPeRA approach may be utilized in 
conventional radiography, which can be adapted by virtually any rheumatology clinic to 
simulate a true control and thereby compare the relative radiographic efficacy of various 
treatments. POPeRA has now both confirmed and informed the results of three large 
randomized clinical trials in early RA: SWEFOT, FIN-RACo, and NEO-RACo.    
In Paper III, survivin was demonstrated in a randomized clinical trial to be a prevalent and 
relevant biomarker for clinical and theranostic response in early RA, signaling a risk for 
worse long-term disease activity upon positivity at diagnosis. Survivin-positive patients are at 
a higher risk for MTX non-response, but appear to benefit more from TT than anti-TNF upon 
MTX failure. 
In Paper IV, being obese upon diagnosis of early RA was shown to be a strong independent 
predictor of non-remission over two years; in addition to female sex, current smoking status, 
and functional disability. These results stress the need to consider lifestyle in randomized 
controlled trials, and to work proactively with patients in changing modifiable risk habits. 
In Paper V, a new approach for integrating Kaltenborn manual mobilization was developed 
and tested in an experimental research group of participants with RA and a clinical 
comparator group with hand OA in a blinded randomized crossover pilot study. Mobilization 
of the MCP II-V joints was found to be a clinically feasible, safe, and potentially effective 
approach of integrative medicine in RA, which merits further testing in larger randomized 
controlled trials. 
To conclude, we established an updated, evidence-based proactive research approach 
investigating if personalized integrative medicine for patients with RA – through the 
application of imaging methods; identification of biomarkers and risk factors; and integration 
of manual therapy – can lead to enhanced, individualized care. The resulting emerging 
evidence suggests that personalized integrative medicine is a strategy that may benefit 
patients with RA. Future studies of individualized and integrative therapeutic approaches in 
RA and other similar autoimmune conditions are warranted.   
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